Gareth Evans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6454656/publications.pdf

Version: 2024-02-01

1,004	86,902	426	748
papers	citations	136 h-index	256 g-index

1056	1056	1056	57995
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC). Journal of Medical Genetics, 2023, 60, 41-47.	1.5	4
2	Predicting the likelihood of aBRCA1/2pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer. Journal of Clinical Pathology, 2023, 76, 684-689.	1.0	0
3	Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, 001-010.	0.4	4
4	Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers. Journal of Medical Genetics, 2022, 59, 328-334.	1.5	7
5	Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers. Journal of Medical Genetics, 2022, 59, 133-140.	1.5	11
6	High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. Journal of Medical Genetics, 2022, 59, 115-121.	1.5	13
7	Back to the future? Reflections on three phases of education policy reform in Wales and their implications for teachers. Journal of Educational Change, 2022, 23, 371-396.	2.5	12
8	Extended gene panel testing in lobular breast cancer. Familial Cancer, 2022, 21, 129-136.	0.9	1
9	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. International Journal of Epidemiology, 2022, 50, 1897-1911.	0.9	43
10	Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1. Journal of Autism and Developmental Disorders, 2022, 52, 1478-1494.	1.7	19
11	PTCH2 is not a strong candidate gene for gorlin syndrome predisposition. Familial Cancer, 2022, 21, 343-346.	0.9	8
12	Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, 75, 69-76.	0.5	9
13	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
14	The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?. International Journal of Cancer, 2022, 150, 73-79.	2.3	24
15	Dominantâ€negative pathogenic variant <scp>BRIP1</scp> c.<scp>1045G</scp>>C is a highâ€risk allele for nonâ€mucinous epithelial ovarian cancer: A caseâ€control study. Clinical Genetics, 2022, 101, 48-54.	1.0	3
16	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	0.8	90
17	Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants. European Journal of Human Genetics, 2022, 30, 458-464.	1.4	6
18	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	2.0	6

#	Article	IF	Citations
19	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
20	Naevoid basal cell carcinoma syndrome. , 2022, , 449-452.		0
21	Womenâ€™s health behaviour change after receiving breast cancer risk estimates with tailored screening and prevention recommendations. BMC Cancer, 2022, 22, 69.	1.1	13
22	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
23	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	3.4	51
24	Inherited Cancer Genetic Epidemiology to Improve Precision Medicine. Journal of Clinical Medicine, 2022, 11, 879.	1.0	0
25	30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes. European Journal of Human Genetics, 2022, 30, 413-419.	1.4	17
26	Abstract P1-10-01: Results from the breast cancer - anti progestin prevention study 1 (BC-APPS1) trial - a novel approach in breast cancer prevention. Cancer Research, 2022, 82, P1-10-01-P1-10-01.	0.4	0
27	Cochlear Implantation in Neurofibromatosis Type 2: Experience From the UK Neurofibromatosis Type 2 Service. Otology and Neurotology, 2022, 43, 538-546.	0.7	6
28	Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk. BMJ, The, 2022, 376, o258.	3.0	1
29	BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?. British Journal of Cancer, 2022, 127, 163-167.	2.9	2
30	ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. European Journal of Human Genetics, 2022, 30, 812-817.	1.4	11
31	Comparison of the frequency of lossâ€ofâ€function LZTR1 variants between schwannomatosis patients and the general population. Human Mutation, 2022, 43, 919-927.	1.1	2
32	Risk perception and disease knowledge in attendees of a community-based lung cancer screening programme. Lung Cancer, 2022, 168, 1-9.	0.9	2
33	A Genome-Wide Gene-Based Geneâ€“Environment Interaction Study of Breast Cancer in More than 90,000 Women. Cancer Research Communications, 2022, 2, 211-219.	0.7	6
34	Reâ€evaluation of missense variant classifications in NF2. Human Mutation, 2022, 43, 643-654.	1.1	5
35	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromesâ€“ a collaborative multicentre endeavour within the project Solve-RD. European Journal of Medical Genetics, 2022, 65, 104475.	0.7	2
36	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Research, 2022, 24, 27.	2.2	15

#	Article	IF	Citations
37	Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel. Genetics in Medicine, 2022, 24, 1485-1494.	1.1	23
38	The feasibility of implementing risk stratification into a national breast cancer screening programme: a focus group study investigating the perspectives of healthcare personnel responsible for delivery. BMC Women's Health, 2022, 22, 142.	0.8	8
39	Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study. Breast, 2022, 64, 47-49.	0.9	5
40	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	3.6	19
41	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Cancers, 2022, 14, 2716.	1.7	10
42	Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK). Genetics in Medicine, 2022, 24, 1867-1877.	1.1	12
43	Neuroanatomical correlates of working memory performance in Neurofibromatosis 1. Cerebral Cortex Communications, 2022, 3, .	0.7	0
44	Development and evaluation of polygenic risk scores for prediction of endometrial cancer risk in European women. Genetics in Medicine, 2022, 24, 1847-1856.	1.1	6
45	Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. Journal of the National Cancer Institute, 2022, 114, 1706-1719.	3.0	14
46	Screening of potential novel candidate genes in schwannomatosis patients. Human Mutation, 2022, 43, 1368-1376.	1.1	3
47	Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing. British Journal of Cancer, 2022, 127, 1116-1122.	2.9	4
48	Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Medicine, 2022, 14, .	3.6	10
49	Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine, 2022, 24, 1967-1977.	1.1	60
50	The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and metaâ€analysis. International Journal of Cancer, 2022, 151, 1626-1639.	2.3	8
51	Cancer risk and tumour spectrum in 172 patients with a germlineSUFUpathogenic variation: a collaborative study of the SIOPE Host Genome Working Group. Journal of Medical Genetics, 2022, 59, 1123-1132.	1.5	4
52	Assessment of mismatch repair deficiency in ovarian cancer. Journal of Medical Genetics, 2021, 58, 687-691.	1.5	13
53	Constitutional de novo deletion CNV encompassing REST predisposes to diffuse hyperplastic perilobar nephroblastomatosis (HPLN). Journal of Medical Genetics, 2021, 58, 581-585.	1.5	3
54	Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro-Oncology, 2021, 23, 1113-1124.	0.6	20

#	Article	IF	Citations
55	The importance of genetic counseling and screening for people with pathogenic <scp>SMARCE1</scp> variants: A family study. American Journal of Medical Genetics, Part A, 2021, 185, 561-565.	0.7	6
56	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	3.0	45
57	Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent. Journal of Medical Genetics, 2021, 58, 74-78.	1.5	5
58	NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro-Oncology, 2021, 23, 100-111.	0.6	27
59	Sporadic vestibular schwannoma: a molecular testing summary. Journal of Medical Genetics, 2021, 58, 227-233.	1.5	11
60	Specialist oncological surgery for removal of the ovaries and fallopian tubes in <scp>BRCA1</scp> and <scp>BRCA2</scp> pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels. International Journal of Cancer, 2021, 148, 1155-1163.	2.3	13
61	A mismatch in care: results of a United Kingdomâ€wide patient and clinician survey of gynaecological services for women with Lynch syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 728-736.	1.1	13
62	UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. Journal of Medical Genetics, 2021, 58, 135-139.	1.5	23
63	Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513.	2.3	9
64	New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer. Familial Cancer, 2021, 20, 1-7.	0.9	8
65	TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes. Gut, 2021, 70, 1139-1146.	6.1	10
66	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	1.1	28
67	Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of â€œStemnessâ€•Programs and Local Inflammation. Clinical Cancer Research, 2021, 27, 1119-1130.	3.2	8
68	Lynch syndrome for the gynaecologist. The Obstetrician and Gynaecologist, 2021, 23, 9-20.	0.2	18
69	Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Human Mutation, 2021, 42, 223-236.	1.1	81
70	The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges. Oncogene, 2021, 40, 875-884.	2.6	13
71	Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. The Lancet Child and Adolescent Health, 2021, 5, 167-177.	2.7	166
72	Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial. International Journal of Gynecological Cancer, 2021, 31, 286-291.	1.2	25

#	Article	IF	Citations
73	European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. British Journal of Surgery, 2021, 108, 484-498.	0.1	130
74	Attitudes towards riskâ€reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 714-726.	1.1	13
75	Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. Journal of Medical Genetics, 2021, 58, 217-226.	1.5	15
76	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	2.9	5
77	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
78	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 305-316.	0.9	20
79	Choose and stay on one out of two paths: distinction between clinical versus research genetic testing to identify cancer predisposition syndromes among patients with cancer. Familial Cancer, 2021, 20, 289-291.	0.9	5
80	Comment on: SMARCB1 Gene Mutation Predisposes to Earlier Development of Glioblastoma: A Case Report of Familial GBM. Journal of Neuropathology and Experimental Neurology, 2021, 80, 289-290.	0.9	1
81	The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. Scientific Reports, 2021, 11, 2847.	1.6	20
82	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	13.9	532
83	Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. Journal of Medical Genetics, 2021, , jmedgenet-2020-107501.	1.5	9
84	Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer, 2021, 124, 1524-1532.	2.9	12
85	Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives. European Journal of Human Genetics, 2021, 29, 861-871.	1.4	6
86	Identifying challenges in neurofibromatosis: a modified Delphi procedure. European Journal of Human Genetics, 2021, 29, 1625-1633.	1.4	7
87	Typical 22q11.2 deletion syndrome appears to confer a reduced risk of schwannoma. Genetics in Medicine, 2021, 23, 1779-1782.	1.1	3
88	Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG). Familial Cancer, 2021, 20, 317-325.	0.9	22
89	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	1.3	11
90	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine, 2021, 23, 1506-1513.	1.1	290

#	Article	IF	Citations
91	Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?. BMC Cancer, 2021, 21, 637.	1.1	15
92	The microenvironment in sporadic and neurofibromatosis type IIâ€“related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. Journal of Neurosurgery, 2021, 134, 1419-1429.	0.9	23
93	Is Breast Cancer Risk Associated with Menopausal Hormone Therapy Modified by Current or Early Adulthood BMI or Age of First Pregnancy?. Cancers, 2021, 13, 2710.	1.7	2
94	Microscopy and chemical analyses reveal flavone-based woolly fibres extrude from micron-sized holes in glandular trichomes of Dionysia tapetodes. BMC Plant Biology, 2021, 21, 258.	1.6	2
95	Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Genetics in Medicine, 2021, 23, 1969-1976.	1.1	8
96	The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study. Cancers, 2021, 13, 3245.	1.7	5
97	A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. European Journal of Human Genetics, 2021, 29, 1354-1358.	1.4	9
98	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
99	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	1.0	11
100	Solving patients with rare diseases through programmatic reanalysis of genome-phenome data. European Journal of Human Genetics, 2021, 29, 1337-1347.	1.4	34
101	Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. Neurology, 2021, 97, S91-S98.	1.5	19
102	Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. Breast Cancer Research and Treatment, 2021, 189, 677-687.	1.1	7
103	Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes. Human Mutation, 2021, 42, 1187-1207.	1.1	5
104	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17.	0.7	34
105	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	5.1	58
106	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
107	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
108	Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study. Cancers, 2021, 13, 4344.	1.7	28

#	Article	IF	Citations
109	Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability. Cancers, 2021, 13, 4154.	1.7	5
110	Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. Cancers, 2021, 13, 4538.	1.7	8
111	Lessons learned from drug trials in neurofibromatosis: A systematic review. European Journal of Medical Genetics, 2021, 64, 104281.	0.7	5
112	Translabyrinthine resection of NF2 associated vestibular schwannoma with cochlear implant insertion. Neurosurgical Focus Video, 2021, 5, V14.	0.1	0
113	Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer. Breast, 2021, 60, 45-52.	0.9	9
114	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	1.1	19
115	Optical coherence tomography significance in managing complex neurofibromatosis 2-related papilledema: Report of a case. JRSM Open, 2021, 12, 205427042098145.	0.2	1
116	From <i>BRCA1</i> to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes. Breast Care, 2021, 16, 202-213.	0.8	7
117	Introducing a low-risk breast screening pathway into the NHS Breast Screening Programme: Views from healthcare professionals who are delivering risk-stratified screening. Women's Health, 2021, 17, 174550652110097.	0.7	13
118	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	5.1	48
119	Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set. JAMA Oncology, 2021, 7, 1800.	3.4	55
120	Testing a breast cancer prevention and a multiple disease prevention weight loss programme amongst women within the UK NHS breast screening programmeâ€"a randomised feasibility study. Pilot and Feasibility Studies, 2021, 7, 220.	0.5	6
121	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
122	Epithelial ovarian cancer risk: A review of the current genetic landscape. Clinical Genetics, 2020, 97, 54-63.	1.0	31
123	A deep intronic SMARCB1 variant associated with schwannomatosis. Clinical Genetics, 2020, 97, 376-377.	1.0	7
124	Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genetics in Medicine, 2020, 22, 53-59.	1.1	64
125	A caseâ€"control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. International Journal of Cancer, 2020, 146, 2122-2129.	2.3	38
126	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	1.1	365

#	Article	IF	Citations
127	Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. Genetics in Medicine, 2020, 22, 398-406.	1.1	26
128	EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro-Oncology, 2020, 22, 31-45.	0.6	190
129	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. European Urology, 2020, 77, 24-35.	0.9	124
130	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
131	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
132	Risk-based breast cancer screening strategies in women. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 3-17.	1.4	48
133	Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women. Journal of Medical Screening, 2020, 27, 130-137.	1.1	21
134	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet, The, 2020, 395, 117-122.	6.3	128
135	Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals. European Urology Oncology, 2020, 3, 764-772.	2.6	39
136	Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication. British Journal of Cancer, 2020, 122, 329-332.	2.9	4
137	Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants. European Journal of Cancer, 2020, 124, 88-90.	1.3	2
138	New evidence confirms that reproductive risk factors can be used to stratify breast cancer risks: Implications for a new population screening paradigm. European Journal of Cancer, 2020, 124, 204-206.	1.3	3
139	Genetic predisposition to cancer. Medicine, 2020, 48, 138-143.	0.2	0
140	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. Breast Cancer Research, 2020, 22, 101.	2.2	19
141	Regarding â€œNeuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade gliomaâ€. Neuro-Oncology Practice, 2020, 7, 572-573.	1.0	2
142	Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. Hereditary Cancer in Clinical Practice, 2020, 18, 20.	0.6	3
143	Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. European Journal of Human Genetics, 2020, 28, 1541-1547.	1.4	22
144	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82

#	Article	IF	Citations
145	Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors. Familial Cancer, 2020, 20, 189-194.	0.9	1
146	Infantile fibrosarcoma with TPM3-NTRK1 fusion in a boy with Bloom syndrome. Familial Cancer, 2020, , 1.	0.9	3
147	BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study. European Journal of Cancer, 2020, 136, 169-175.	1.3	26
148	Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholdersâ€™ views on a low-risk breast screening pathway. BMC Cancer, 2020, 20, 680.	1.1	27
149	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. Journal of Clinical Medicine, 2020, 9, 2290.	1.0	12
150	Future Research Suggestions for Multigene Testing in Unselected Populationsâ€”Reply. JAMA Oncology, 2020, 6, 785.	3.4	0
151	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
152	The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. PLoS Medicine, 2020, 17, e1003263.	3.9	58
153	Reply to Kratz et al.. European Journal of Human Genetics, 2020, 28, 1483-1485.	1.4	4
154	Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.7	12
155	Heritability of mammographic breast density. Quantitative Imaging in Medicine and Surgery, 2020, 10, 2387-2391.	1.1	4
156	Germline TP53 Testing in Breast Cancers: Why, When and How?. Cancers, 2020, 12, 3762.	1.7	16
157	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
158	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 2020, 583, 90-95.	13.7	148
159	Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. British Journal of Cancer, 2020, 123, 268-274.	2.9	20
160	Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY). Journal of Medical Genetics, 2020, 57, 226-236.	1.5	15
161	Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. Human Mutation, 2020, 41, 1555-1562.	1.1	16
162	Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genetics in Medicine, 2020, 22, 1524-1532.	1.1	44

#	Article	IF	Citations
163	Response to Benusiglio et al.. Genetics in Medicine, 2020, 22, 1424-1425.	1.1	1
164	Guidelines for the Liâ€“Fraumeni and heritable TP53-related cancer syndromes. European Journal of Human Genetics, 2020, 28, 1379-1386.	1.4	167
165	Characterising the loss-of-function impact of 5â€™ untranslated region variants in 15,708 individuals. Nature Communications, 2020, 11, 2523.	5.8	99
166	Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. European Journal of Human Genetics, 2020, 28, 1387-1393.	1.4	63
167	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	13.7	338
168	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	1.1	7
169	Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. Journal of Medical Genetics, 2020, 57, 829-834.	1.5	30
170	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	12.5	178
171	Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer. Journal of Clinical Medicine, 2020, 9, 1842.	1.0	10
172	Prostate Cancer Risk by BRCA2 Genomic Regions. European Urology, 2020, 78, 494-497.	0.9	6
173	Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet, The, 2020, 395, 1855-1863.	6.3	220
174	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer, 2020, 20, 570.	1.1	37
175	Long-Term Evaluation of a UK Community Pharmacy-Based Weight Management Service. Pharmacy (Basel, Switzerland), 2020, 8, 22.	0.6	4
176	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United) Tj ETQq0 0 0 rgBT /Overlock 10	2.9	21
177	European womenâ€™s perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: a qualitative study. BMC Cancer, 2020, 20, 247.	1.1	19
178	The inflammatory microenvironment in vestibular schwannoma. Neuro-Oncology Advances, 2020, 2, vdaa023.	0.4	35
179	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
180	Global burden of childhood and adolescent cancer. Chinese Clinical Oncology, 2020, 9, 56-56.	0.4	0

#	Article	IF	Citations
181	Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer. Cancers, 2020, 12, 378.	1.7	21
182	Neurofibromatosis type 2 discordance in monozygous twins. Familial Cancer, 2020, 19, 37-40.	0.9	2
183	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	1.1	24
184	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	5.8	30
185	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	2.2	41
186	Perceived fatigue in children and young adults with neurofibromatosis type 1. Journal of Paediatrics and Child Health, 2020, 56, 878-883.	0.4	12
187	Association between genetic polymorphisms and endometrial cancer risk: a systematic review. Journal of Medical Genetics, 2020, 57, 591-600.	1.5	28
188	Germline and sporadic cancers driven by the RAS pathway: parallelsÂandÂcontrasts. Annals of Oncology, 2020, 31, 873-883.	0.6	35
189	Autism Spectrum Disorder Symptom Profile Across the RASopathies. Frontiers in Psychiatry, 2020, 11, 585700.	1.3	9
190	Clinical and neuroradiological characterisation of spinal lesions in adults with Neurofibromatosis type 1. Journal of Clinical Neuroscience, 2020, 77, 98-105.	0.8	11
191	The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women. BMC Cancer, 2020, 20, 452.	1.1	23
192	Automatic density prediction in low dose mammography. , 2020, , .		5
193	505â€…Attitudes towards risk reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. , 2020, , .		0
194	507â€…Surgical decision making in premenopausal brca carriers considering risk reducing early-salpingectomy or salpingo-oophorectomy: a qualitative study. , 2020, , .		0
195	Screening strategy modification based on personalized breast cancer risk stratification and its implementation in the national guidelines â€“ pilot study. Zdravstveno Varstvo, 2020, 59, 211-218.	0.6	3
196	Sarcoma in neurofibromatosis 2: case report and review of the literature. Familial Cancer, 2019, 18, 97-100.	0.9	3
197	Psychosocial impact of undergoing prostate cancer screening for men with <scp>BRCA</scp>1 or <scp>BRCA</scp>2 mutations. BJU International, 2019, 123, 284-292.	1.3	9
198	Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations. Supportive Care in Cancer, 2019, 27, 297-309.	1.0	11

#	Article	IF	Citations
199	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. Histopathology, 2019, 75, 813-824.	1.6	19
200	Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Scientific Reports, 2019, 9, 10351.	1.6	75
201	The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 781-794.	0.9	37
202	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
203	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. EBioMedicine, 2019, 48, 203-211.	2.7	14
204	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28.	0.6	27
205	Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?. Familial Cancer, 2019, 18, 377-379.	0.9	5
206	Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. PLoS ONE, 2019, 14, e0221419.	1.1	22
207	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
208	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	0.9	148
209	A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncology, 2019, 5, 1718.	3.4	91
210	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
211	Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. Journal of Medical Genetics, 2019, 56, 301-307.	1.5	21
212	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	1.1	102
213	An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genetics in Medicine, 2019, 21, 2706-2712.	1.1	11
214	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
215	Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant. Familial Cancer, 2019, 18, 445-449.	0.9	2
216	Germline selection shapes human mitochondrial DNA diversity. Science, 2019, 364, .	6.0	178

#	Article	IF	Citations
217	Confirmation that somatic mutations of betaâ€2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial. Histopathology, 2019, 75, 236-246.	1.6	15
218	The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genetics in Medicine, 2019, 21, 2167-2180.	1.1	139
219	Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. Clinical Genetics, 2019, 96, 151-162.	1.0	18
220	Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. European Journal of Cancer Prevention, 2019, 28, 500-506.	0.6	6
221	Cancer surveillance, obesity, and potential bias. Lancet Public Health, The, 2019, 4, e218.	4.7	0
222	Comparison of a Standard Resolution PET-CT Scanner With an HRRT Brain Scanner for Imaging Small Tumors Within the Head. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 434-443.	2.7	10
223	Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). Journal of Pathology: Clinical Research, 2019, 5, 189-198.	1.3	18
224	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
225	Concern regarding classification of germline TP53 variants as likely pathogenic. Human Mutation, 2019, 40, 828-831.	1.1	8
226	A Micro-Costing Study of Screening for Lynch Syndrome-Associated Pathogenic Variants in an Unselected Endometrial Cancer Population: Cheap as NGS Chips?. Frontiers in Oncology, 2019, 9, 61.	1.3	8
227	Women's perceptions of personalized riskâ€based breast cancer screening and prevention: An international focus group study. Psycho-Oncology, 2019, 28, 1056-1062.	1.0	39
228	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	1.1	153
229	Neurosurgical contribution within a complex NF1 supraregional service. Clinical Neurology and Neurosurgery, 2019, 180, 18-24.	0.6	2
230	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	0.6	42
231	Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Breast Cancer Research and Treatment, 2019, 176, 141-148.	1.1	56
232	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
233	Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1184-1187.	0.9	4
234	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. European Journal of Epidemiology, 2019, 34, 591-600.	2.5	16

#	Article	IF	Citations
235	Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35â€“39 at Increased Familial Risk of Breast Cancer. EClinicalMedicine, 2019, 7, 39-46.	3.2	7
236	Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. Breast, 2019, 45, 1-6.	0.9	21
237	Identifying modifiable and non-modifiable risk factors of epithelial ovarian cancerâ€”can we get it better?. Gynecology and Pelvic Medicine, 2019, 2, 21-21.	0.1	0
238	[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma. Otology and Neurotology, 2019, 40, 826-835.	0.7	6
239	Neurofibromatosis type 2 and related disorders. Current Opinion in Oncology, 2019, 31, 562-567.	1.1	20
240	Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials. BMC Cancer, 2019, 19, 1089.	1.1	21
241	Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. Scientific Reports, 2019, 9, 18555.	1.6	13
242	Rapid reversal of clinical downâ€classification of a BRCA1 splicing variant avoiding psychological harm. Clinical Genetics, 2019, 95, 532-533.	1.0	2
243	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
244	Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study. Clinical Breast Cancer, 2019, 19, e116-e126.	1.1	19
245	European Breast Cancer Council manifesto 2018: GeneticÂrisk prediction testing in breast cancer. European Journal of Cancer, 2019, 106, 45-53.	1.3	15
246	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancerâ€”an European consensus statement and expert recommendations. European Journal of Cancer, 2019, 106, 54-60.	1.3	25
247	Global Disparities in Breast Cancer Genetics Testing, Counselling and Management. World Journal of Surgery, 2019, 43, 1264-1270.	0.8	18
248	Are women with pathogenic variants in PMS2 and MSH6 really at high lifetime risk of breast cancer?. Genetics in Medicine, 2019, 21, 1878-1879.	1.1	6
249	Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene MSH6. JAMA Oncology, 2019, 5, 119.	3.4	0
250	Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro-Oncology, 2019, 21, 314-325.	0.6	59
251	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
252	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. Familial Cancer, 2019, 18, 281-284.	0.9	17

#	Article	IF	Citations
253	Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 gene. Laryngoscope, 2019, 129, 967-973.	1.1	15
254	Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. Journal of Medical Genetics, 2019, 56, 209-219.	1.5	26
255	Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genetics in Medicine, 2019, 21, 1525-1533.	1.1	47
256	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	0.9	81
257	Prediction of reader estimates of mammographic density using convolutional neural networks. Journal of Medical Imaging, 2019, 6, 1.	0.8	28
258	Gliomas in the context of Li-Fraumeni syndrome: An international cohort.. Journal of Clinical Oncology, 2019, 37, 1517-1517.	0.8	6
259	C2 neurofibromas in neurofibromatosis type 1: genetic and imaging characteristics. Journal of Neurosurgery: Spine, 2019, 30, 126-132.	0.9	8
260	Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer. Frontiers in Immunology, 2019, 10, 3023.	2.2	45
261	Neurofibromatosis type 2 service delivery in England. Neurochirurgie, 2018, 64, 375-380.	0.6	16
262	Population-based testing of non-mucinous epithelial ovarian cancer in Scotland. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1459-1459.	1.1	1
263	Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. Journal of Medical Genetics, 2018, 55, 442-448.	1.5	1
264	PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 647-658.	1.1	58
265	Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndromeâ€"Reply. JAMA Oncology, 2018, 4, 890.	3.4	2
266	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
267	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. JAMA Oncology, 2018, 4, 476.	3.4	109
268	Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting BRCA1/2 mutations in a Southeast Asian country. Journal of Medical Genetics, 2018, 55, 344-350.	1.5	5
269	Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues. Breast, 2018, 37, 148-153.	0.9	17
270	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844â€"848. American Journal of Human Genetics, 2018, 102, 69-87.	2.6	144

#	Article	IF	Citations
271	Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer. Patient Education and Counseling, 2018, 101, 779-788.	1.0	21
272	Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncology, The, 2018, 19, 169-180.	5.1	316
273	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. American Journal of Obstetrics and Gynecology, 2018, 218, 431.e1-431.e12.	0.7	32
274	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	2.9	12
275	Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). Molecular Autism, 2018, 9, 12.	2.6	52
276	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. The Lancet Gastroenterology and Hepatology, 2018, 3, 489-498.	3.7	87
277	Personalized prevention in high risk individuals: Managing hormones and beyond. Breast, 2018, 39, 139-147.	0.9	18
278	Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. Archives of Disease in Childhood, 2018, 103, 463-469.	1.0	23
279	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in Medicine, 2018, 20, 1575-1582.	1.1	15
280	A Novel <i>PTCH1 </i>Frameshift Mutation Leading to Nevoid Basal Cell Carcinoma Syndrome. Cytogenetic and Genome Research, 2018, 154, 57-61.	0.6	6
281	Are we ready for the challenge of implementing risk-based breast cancer screening and primary prevention?. Breast, 2018, 39, 24-32.	0.9	30
282	Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	6.1	410
283	High-Grade Glioma is not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient. Neurosurgery, 2018, 83, 193-196.	0.6	10
284	An update on the diagnosis and treatment of vestibular schwannoma. Expert Review of Neurotherapeutics, 2018, 18, 29-39.	1.4	81
285	CNVs affecting cancer predisposing genes (CPGs) detected as incidental findings in routine germline diagnostic chromosomal microarray (CMA) testing. Journal of Medical Genetics, 2018, 55, 89-96.	1.5	7
286	Spinal ependymomas in NF2: a surgical disease?. Journal of Neuro-Oncology, 2018, 136, 605-611.	1.4	24
287	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 58-66.	1.1	3
288	Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 167, 779-785.	1.1	9

#	Article	IF	Citations
289	Low Lifetime Risk of Contralateral Breast Cancer in a Middleâ€Income Asian Country: Evidence to Guide Postâ€treatment Surveillance. World Journal of Surgery, 2018, 42, 1270-1277.	0.8	0
290	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	1.4	21
291	Gene panel testing for breast cancer should not be used to confirm syndromic gene associations. Npj Genomic Medicine, 2018, 3, 32.	1.7	6
292	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	1.4	33
293	Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture. EBioMedicine, 2018, 36, 508-516.	2.7	1
294	Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect. Breast Cancer Research and Treatment, 2018, 171, 435-442.	1.1	73
295	â€˜For me it's about not feeling like I'm on a dietâ€™: a thematic analysis of women's experiences of an intermittent energy restricted diet to reduce breast cancer risk. Journal of Human Nutrition and Dietetics, 2018, 31, 773-780.	1.3	8
296	Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient. Neurosurgery, 2018, 83, 38-42.	0.6	24
297	A Dominantly Inherited 5â€² UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. American Journal of Human Genetics, 2018, 103, 213-220.	2.6	78
298	NFM-04. INITIAL MANAGEMENT STRATEGY AS A DISCRIMINATOR OF VISUAL OUTCOME IN CHILDREN PRESENTING WITH NEUROFIBROMATOSIS TYPE 1 AND OPTIC PATHWAY GLIOMA - RESULTS FROM A SOCIÃ‰TÃ‰ INTERNATIONALE Dâ€™ONCOLOGIE PÃ‰DIATRIQUE EUROPE (SIOPE) CLINICAL TRIALS WORKSHOP. Neuro-Oncology, 2018, 20, i143-i143.	0.6	1
299	White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. Annals of Internal Medicine, 2018, 168, 326.	2.0	37
300	Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds. Breast Cancer Research, 2018, 20, 49.	2.2	8
301	Fanconi anemia with sun-sensitivity caused by a Xeroderma pigmentosum-associated missense mutation in XPF. BMC Medical Genetics, 2018, 19, 7.	2.1	9
302	Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. BMC Public Health, 2018, 18, 178.	1.2	18
303	Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds. Hereditary Cancer in Clinical Practice, 2018, 16, 4.	0.6	7
304	A comparison of five methods of measuring mammographic density: a case-control study. Breast Cancer Research, 2018, 20, 10.	2.2	77
305	Psychological impact of providing women with personalised 10-year breast cancer risk estimates. British Journal of Cancer, 2018, 118, 1648-1657.	2.9	41
306	The prevalence of Lynch syndrome in women with endometrial cancer: a systematic review protocol. Systematic Reviews, 2018, 7, 121.	2.5	15

#	Article	IF	Citations
307	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18.	2.6	46
308	Women's decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals. PLoS ONE, 2018, 13, e0197772.	1.1	27
309	Schwannomatosis: a genetic and epidemiological study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1215-1219.	0.9	111
310	Reader performance in visual assessment of breast density using visual analogue scales: are some readers more predictive of breast cancer?. , 2018, , .		0
311	Risk-reducing mastectomy rates in the US: A closer examination of the Angelina Jolie effect.. Journal of Clinical Oncology, 2018, 36, e13557-e13557.	0.8	0
312	Using a convolutional neural network to predict readers' estimates of mammographic density for breast cancer risk assessment. , 2018, , .		0
313	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472.	6.1	411
314	Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. Gynecologic Oncology, 2017, 144, 491-495.	0.6	71
315	Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Familial Cancer, 2017, 16, 433-440.	0.9	52
316	Identifying High-Risk Women for Endometrial Cancer Prevention Strategies: Proposal of an Endometrial Cancer Risk Prediction Model. Cancer Prevention Research, 2017, 10, 1-13.	0.7	68
317	The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. Proceedings of SPIE, 2017, 10134, .	0.8	0
318	The BRCA1/2 Parent-of-Origin Effect on Breast Cancer Riskâ€"Letter. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 284-284.	1.1	4
319	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a caseâ€“control study. Journal of Medical Genetics, 2017, 54, 111-113.	1.5	56
320	Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. Journal of Neuro-Oncology, 2017, 131, 117-124.	1.4	39
321	Does the prediction of breast cancer improve using a combination of mammographic density measures compared to individual measures alone?. Proceedings of SPIE, 2017, , .	0.8	0
322	Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD). BMC Medical Genetics, 2017, 18, 40.	2.1	25
323	Pathology update to the Manchester Scoring System based on testing in over 4000 families. Journal of Medical Genetics, 2017, 54, 674-681.	1.5	51
324	Visual assessment of breast density using Visual Analogue Scales: observer variability, reader attributes and reading time. , 2017, , .		3

#	Article	IF	Citations
325	Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. Clinical Cancer Research, 2017, 23, e46-e53.	3.2	133
326	Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clinical Cancer Research, 2017, 23, e54-e61.	3.2	76
327	Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clinical Cancer Research, 2017, 23, e62-e67.	3.2	139
328	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
329	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45.	3.2	358
330	Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. Value in Health, 2017, 20, 1100-1109.	0.1	46
331	First evidence of genotypeâ€“phenotype correlations in Gorlin syndrome. Journal of Medical Genetics, 2017, 54, 530-536.	1.5	56
332	Cranial irradiation in childhood mimicking neurofibromatosis type II. American Journal of Medical Genetics, Part A, 2017, 173, 1635-1639.	0.7	2
333	Neurofibromatosis type 2: Multiple intraâ€dermal tumors in a toddler. American Journal of Medical Genetics, Part A, 2017, 173, 1447-1449.	0.7	2
334	Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664.	6.1	127
335	Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ: British Medical Journal, 2017, 356, j1388.	2.4	20
336	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
337	Hearing optimisation in neurofibromatosis type 2: A systematic review. Clinical Otolaryngology, 2017, 42, 1329-1337.	0.6	40
338	The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2. Journal of Neurosurgery: Spine, 2017, 26, 474-482.	0.9	25
339	False-negative MRI breast screening in high-risk women. Clinical Radiology, 2017, 72, 207-216.	0.5	17
340	Genetic Severity Score predicts clinical phenotype in NF2. Journal of Medical Genetics, 2017, 54, 657-664.	1.5	87
341	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. European Journal of Radiology, 2017, 94, 133-139.	1.2	8
342	Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults. JAMA Neurology, 2017, 74, 1123.	4.5	63

#	Article	IF	Citations
343	O15 Bioaccessibility of organosulphur compounds from Allium sativum. Biochemical Pharmacology, 2017, 139, 114.	2.0	0
344	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	3.4	148
345	Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome. JAMA Oncology, 2017, 3, 1702.	3.4	125
346	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Obstetrical and Gynecological Survey, 2017, 72, 338-340.	0.2	1
347	Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Research and Treatment, 2017, 165, 433-444.	1.1	31
348	Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. Familial Cancer, 2017, 16, 173-179.	0.9	2
349	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. Clinical Cancer Research, 2017, 23, e107-e114.	3.2	91
350	Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American Journal of Obstetrics and Gynecology, 2017, 217, 578.e1-578.e12.	0.7	63
351	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
352	Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1 -related schwannomatosis. Neurology, 2017, 88, 87-92.	1.5	104
353	Creation of an international registry to support discovery in schwannomatosis. American Journal of Medical Genetics, Part A, 2017, 173, 407-413.	0.7	13
354	Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	160
355	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	0.9	45
356	353 C2 Segmental Neurofibromas in Patients with Neurofibromatosis Type 1. Neurosurgery, 2017, 64, 280-281.	0.6	0
357	Increased risk of breast cancer in neurofibromatosis type 1: current insights. Breast Cancer: Targets and Therapy, 2017, Volume 9, 531-536.	1.0	31
358	Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists. PLoS ONE, 2017, 12, e0178447.	1.1	9
359	Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hereditary Cancer in Clinical Practice, 2017, 15, 18.	0.6	49
360	A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies. Breast Cancer Research, 2017, 19, 114.	2.2	34

#	Article	IF	Citations
361	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of Clinical Oncology, 2017, 35, 1411-1420.	0.8	148
362	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
363	BRCA and lynch syndrome-associated ovarian cancers behave differently. Gynecologic Oncology Reports, 2017, 22, 108-109.	0.3	11
364	ACTA OTORHINOLARYNGOLOGICA ITALICA. Acta Otorhinolaryngologica Italica, 2016, 36, 345-367.	0.7	49
365	Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England. Annals of the Royal College of Surgeons of England, 2016, 98, 121-127.	0.3	4
366	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
367	Finding Common Ground: Negotiating Across Cultures on Peace and Security Issues. Global Policy, 2016, 7, 458-463.	1.0	0
368	Breast cancer risk feedback to women in the UK NHS breast screening population. British Journal of Cancer, 2016, 114, 1045-1052.	2.9	73
369	Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only. EBioMedicine, 2016, 7, 212-220.	2.7	69
370	What Is the Malignancy Risk in Neurofibromatosis Type 1?. Journal of Clinical Oncology, 2016, 34, 1967-1969.	0.8	8
371	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	2.6	21
372	A heritable form of SMARCE1-related meningiomas with important implications for follow-up and family screening. Neurogenetics, 2016, 17, 83-89.	0.7	47
373	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
374	Biochemical Insights into Merlin/NF2 Pathophysiology and Biologically Targeted Therapies in Childhood NF2 and Related Forms. Journal of Pediatric Biochemistry, 2016, 05, 120-130.	0.2	0
375	Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology, 2016, 87, S40-8.	1.5	23
376	Current whole-body MRI applications in the neurofibromatoses. Neurology, 2016, 87, S31-9.	1.5	65
377	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
378	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78

#	Article	IF	Citations
379	Outcomes of cochlear implantation in patients with neurofibromatosis type 2. Cochlear Implants International, 2016, 17, 172-177.	0.5	26
380	Auditory Brainstem Implantation in Neurofibromatosis Type 2. Otology and Neurotology, 2016, 37, 1267-1274.	0.7	30
381	Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. Breast Cancer Research, 2016, 18, 57.	2.2	37
382	Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing. European Journal of Human Genetics, 2016, 24, 1591-1597.	1.4	26
383	Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hereditary Cancer in Clinical Practice, 2016, 14, 8.	0.6	47
384	Is there really an increased risk of early colorectal cancer in women with BRCA1 pathogenic mutations?. Clinical Genetics, 2016, 89, 399-399.	1.0	7
385	National survey of patients with Gorlin syndrome highlights poor awareness, multiple treatments and profound psychosocial impact of disease. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 371-373.	1.3	3
386	Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncology Practice, 2016, 3, 281-289.	1.0	39
387	Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. Neuro-Oncology, 2016, 18, 275-282.	0.6	27
388	MRI Screening in Women With a Personal History of Breast cancer. Journal of the National Cancer Institute, 2016, 108, djv373.	3.0	6
389	The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes. Human Mutation, 2016, 37, 250-256.	1.1	65
390	No strong evidence for increased risk of breast cancer 8â€“26 years after multiple mammograms in their 30s in females at moderate and high familial risk. British Journal of Radiology, 2016, 89, 20150960.	1.0	2
391	Genetic predisposition to cancer. Medicine, 2016, 44, 65-68.	0.2	2
392	Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Research and Treatment, 2016, 155, 597-601.	1.1	29
393	Genetic testing in a cohort of young patients with HER2-amplified breast cancer. Annals of Oncology, 2016, 27, 467-473.	0.6	21
394	Risk of contralateral breast cancer amongst BRCA1/2 mutation carriers. Translational Cancer Research, 2016, 5, S1066-S1069.	0.4	2
395	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants for Applied Research, 2016, 4, 1-210.	0.4	75
396	Mammographic Density Over Time in Women With and Without Breast Cancer. Lecture Notes in Computer Science, 2016, , 291-298.	1.0	1

#	Article	IF	Citations
397	Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer. , 2016, , 165-187.		0
398	Should We Adjust Visually Assessed Mammographic Density for Observer Variability?. Lecture Notes in Computer Science, 2016, , 540-547.	1.0	0
399	Variations in Breast Density and Mammographic Risk Factors in Different Ethnic Groups. Lecture Notes in Computer Science, 2016, , 510-517.	1.0	0
400	Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-Î¹B Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine, 2015, 2, 1331-1339.	2.7	49
401	Can the breast screening appointment be used to provide risk assessment and prevention advice?. Breast Cancer Research, 2015, 17, 84.	2.2	30
402	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Research, 2015, 17, 147.	2.2	186
403	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
404	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	2.2	26
405	Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. Breast Cancer Research, 2015, 17, 143.	2.2	77
406	Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Colorectal Disease, 2015, 17, 38-46.	0.7	63
407	Cognition in children with neurofibromatosis type 1: data from a populationâ€based study. Developmental Medicine and Child Neurology, 2015, 57, 645-651.	1.1	43
408	In Silico Analysis of NF2 Gene Missense Mutations in Neurofibromatosis Type 2. Otology and Neurotology, 2015, 36, 908-914.	0.7	13
409	Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies. International Journal of Surgical Oncology, 2015, 2015, 1-7.	0.3	15
410	Can Diet and Lifestyle Prevent Breast Cancer: What Is the Evidence?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e66-e73.	1.8	75
411	Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome. European Journal of Human Genetics, 2015, 23, 708-710.	1.4	10
412	Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology, 2015, 84, 141-147.	1.5	90
413	Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography. Breast Cancer Research and Treatment, 2015, 152, 87-94.	1.1	2
414	Autism Spectrum Disorder Profile in Neurofibromatosis Type I. Journal of Autism and Developmental Disorders, 2015, 45, 1649-1657.	1.7	54

#	Article	IF	Citations
415	TheBRCA2polymorphic stop codon: stuff or nonsense?. Journal of Medical Genetics, 2015, 52, 642-645.	1.5	12
416	Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 2015, 372, 2243-2257.	13.9	764
417	Local mammographic density as a predictor of breast cancer. Proceedings of SPIE, 2015, , .	0.8	2
418	Multifocality in neurofibromatosis type 2. Neuro-Oncology, 2015, 17, 481-482.	0.6	5
419	Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. Journal of Medical Genetics, 2015, 52, 557-562.	1.5	40
420	Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms. Seminars in Pediatric Neurology, 2015, 22, 240-258.	1.0	68
421	Integrated smartcard solutions: do people want one card for all their services?. Transportation Planning and Technology, 2015, 38, 534-551.	0.9	4
422	Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey. Clinical Genetics, 2015, 87, 517-524.	1.0	18
423	Rail grinding for the 21st century â€“ taking a lead from the aerospace industry. Proceedings of the Institution of Mechanical Engineers, Part F: Journal of Rail and Rapid Transit, 2015, 229, 457-465.	1.3	20
424	Human in vivo and in vitro studies on gastrointestinal absorption of titanium dioxide nanoparticles. Toxicology Letters, 2015, 233, 95-101.	0.4	98
425	Beliefs about weight and breast cancer: an interview study with high risk women following a 12Âmonth weight loss intervention. Hereditary Cancer in Clinical Practice, 2015, 13, 1.	0.6	25
426	Levels of soya aeroallergens during dockside unloading as measured by personal and static sampling / Razine aeroalergena soje za vrijeme iskrcavanja na luÄkom doku. Arhiv Za Higijenu Rada I Toksikologiju, 2015, 66, 23-29.	0.4	4
427	Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Familial Cancer, 2015, 14, 531-538.	0.9	45
428	Bilateral vestibular schwannomas in older patients: NF2 or chance?. Journal of Medical Genetics, 2015, 52, 422-424.	1.5	33
429	20. Breast surgeons' attitudes towards bilateral risk reducing mastectomy â€“ A comparison between the UK, the US, France and Germany. European Journal of Surgical Oncology, 2015, 41, S23.	0.5	1
430	Lynch syndrome caused byMLH1mutations is associated with an increased risk of breast cancer: a cohort study. Journal of Medical Genetics, 2015, 52, 553-556.	1.5	60
431	SMARCE1 mutations in pediatric clear cell meningioma: case report. Journal of Neurosurgery: Pediatrics, 2015, 16, 296-300.	0.8	26
432	Pathogenesis and management of type 2 neurofibromatosis. Expert Opinion on Orphan Drugs, 2015, 3, 281-292.	0.5	0

#	Article	IF	Citations
433	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	3.0	56
434	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
435	General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles. BMC Cancer, 2015, 15, 243.	1.1	6
436	Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. Familial Cancer, 2015, 14, 521-530.	0.9	14
437	Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. Journal of Clinical Oncology, 2015, 33, 3591-3597.	0.8	91
438	Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. Journal of Medical Genetics, 2015, 52, 699-705.	1.5	78
439	The Manchester guidelines for contralateral risk-reducing mastectomy. World Journal of Surgical Oncology, 2015, 13, 237.	0.8	31
440	A clinical and genetic analysis of multiple primary cancer referrals to genetics services. European Journal of Human Genetics, 2015, 23, 581-587.	1.4	21
441	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. European Urology, 2015, 68, 186-193.	0.9	279
442	Progress of hearing loss in neurofibromatosis type 2: implications for future management. European Archives of Oto-Rhino-Laryngology, 2015, 272, 3143-3150.	0.8	14
443	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
444	Pediatric intracranial clear cell meningioma associated with a germline mutation of SMARCE1: a novel case. Child's Nervous System, 2015, 31, 441-447.	0.6	30
445	Abstract P5-12-01: Predicting the effect of tamoxifen on the breast: Change in measures of breast density, serum markers and SNPs. , 2015, , .		0
446	Breast surgeons' attitudes towards bilateral risk-reducing mastectomy: A National Survey of American Surgeons.. Journal of Clinical Oncology, 2015, 33, 25-25.	0.8	3
447	Dealing with family history of breast cancer: something new, something old. British Journal of General Practice, 2014, 64, 6-7.	0.7	5
448	BCRT response to Moller. Breast Cancer Research and Treatment, 2014, 148, 693-693.	1.1	1
449	Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?. BMC Medical Informatics and Decision Making, 2014, 14, 87.	1.5	9
450	Clinical response to bevacizumab in schwannomatosis. Neurology, 2014, 83, 1986-1987.	1.5	33

#	Article	IF	Citations
451	Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. British Journal of Cancer, 2014, 110, 1681-1687.	2.9	77
452	Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. British Journal of Cancer, 2014, 110, 827-828.	2.9	32
453	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
454	Review of radiation therapy services for neurofibromatosis (NF2) patients in England. British Journal of Neurosurgery, 2014, 28, 16-19.	0.4	7
455	Current Concepts in Management of Vestibular Schwannomas in Neurofibromatosis Type 2. Current Otorhinolaryngology Reports, 2014, 2, 248-255.	0.2	0
456	Germline Mutations in SUFU Cause Gorlin Syndromeâ€“Associated Childhood Medulloblastoma and Redefine the Risk Associated With PTCH1 Mutations. Journal of Clinical Oncology, 2014, 32, 4155-4161.	0.8	236
457	The Fragile X Protein binds mRNA s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2014, 6, 567-568.	3.3	0
458	Response to Santoro et al. Breast Cancer Research and Treatment, 2014, 147, 689-689.	1.1	0
459	Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2014, 148, 397-406.	1.1	56
460	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
461	Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. Cancer Prevention Research, 2014, 7, 993-1001.	0.7	37
462	Ipsilateral Cochlear Implantation After Cochlear Nerve Preserving Vestibular Schwannoma Surgery in Patients With Neurofibromatosis Type 2. Otology and Neurotology, 2014, 35, 43-51.	0.7	66
463	The Genetics of Vestibular Schwannoma. Current Otorhinolaryngology Reports, 2014, 2, 226-234.	0.2	8
464	Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1018-1024.	1.1	13
465	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
466	Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners' and breast surgeons' current practice and preferred practice responsibilities. Journal of Community Genetics, 2014, 5, 69-79.	0.5	16
467	Cancer risk and genotypeâ€“phenotype correlations in PTEN hamartoma tumor syndrome. Familial Cancer, 2014, 13, 57-63.	0.9	119
468	Mammographic surveillance in women aged 35â€“39 at enhanced familial risk of breast cancer (FH02). Familial Cancer, 2014, 13, 13-21.	0.9	13

#	Article	IF	Citations
469	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	0.9	195
470	MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Research and Treatment, 2014, 145, 663-672.	1.1	133
471	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Familial Cancer, 2014, 13, 189-196.	0.9	22
472	Fanconi anaemia,BRCA2mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling. Journal of Medical Genetics, 2014, 51, 71-75.	1.5	48
473	A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. International Journal of Cancer, 2014, 134, 939-947.	2.3	22
474	Nuclear Deterrence in Asia and the Pacific. Asia and the Pacific Policy Studies, 2014, 1, 91-111.	0.6	4
475	Germline <scp>SMARCE1</scp> mutations predispose to both spinal and cranial clear cell meningiomas. Journal of Pathology, 2014, 234, 436-440.	2.1	108
476	TumourMLH1promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). Journal of Medical Genetics, 2014, 51, 789-796.	1.5	69
477	Update from the 2013 international neurofibromatosis conference. American Journal of Medical Genetics, Part A, 2014, 164, 2969-2978.	0.7	17
478	Long-term prospective clinical follow-up afterBRCA1/2presymptomatic testing:BRCA2risks higher than in adjusted retrospective studies. Journal of Medical Genetics, 2014, 51, 573-580.	1.5	15
479	Management of women at high risk of breast cancer. BMJ, The, 2014, 348, g2756-g2756.	3.0	29
480	Risk determination and prevention of breast cancer. Breast Cancer Research, 2014, 16, 446.	2.2	248
481	Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. Journal of Neurology, 2014, 261, 963-969.	1.8	39
482	Intronic splicing mutations in PTCH1 cause Gorlin syndrome. Familial Cancer, 2014, 13, 477-480.	0.9	27
483	Contralateral risk reducing mastectomy â€“ The Manchester experience. European Journal of Surgical Oncology, 2014, 40, 618.	0.5	1
484	SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors. Cancer Genetics, 2014, 207, 373-378.	0.2	71
485	Threshold for genetic testing in women with breast cancer needs to be determined. BMJ, The, 2014, 348, g1863-g1863.	3.0	1
486	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Research, 2014, 16, 442.	2.2	252

#	Article	IF	Citations
487	Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). Oncotarget, 2014, 5, 8223-8234.	0.8	22
488	Cranial Meningioma in Neurofibromatosis Type 2 Patients: Role of Mutations. Tumors of the Central Nervous System, 2014, , 271-276.	0.1	0
489	The genetics of breast cancer, risk-reducing surgery and prevention. , 2014, , 127-145.		0
490	Small Bowel Cancer in the UK. American Journal of Gastroenterology, 2014, 109, S116-S117.	0.2	0
491	Evaluating Transport Technologies for Mitigating the Impact of Emergency Events: Findings from the SAVE ME Project. International Journal of Transportation, 2014, 2, 73-94.	0.4	0
492	Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives. Breast Cancer Research, 2013, 15, 401.	2.2	1
493	Neurofibromatosis type 2 (NF2). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 957-967.	1.0	66
494	Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Research and Treatment, 2013, 140, 135-142.	1.1	144
495	Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nature Genetics, 2013, 45, 295-298.	9.4	208
496	Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 1748-1757.	0.8	641
497	Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. Journal of the National Cancer Institute, 2013, 105, 812-822.	3.0	753
498	Evaluation of <scp>SDHB</scp>,<scp> SDHD</scp> and <scp>VHL</scp> gene susceptibility testing in the assessment of individuals with nonâ€syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clinical Endocrinology, 2013, 78, 898-906.	1.2	62
499	Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. British Journal of Surgery, 2013, 100, 1719-1731.	0.1	104
500	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
501	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
502	Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Research and Treatment, 2013, 142, 611-618.	1.1	58
503	Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2. British Journal of Neurosurgery, 2013, 27, 446-453.	0.4	27
504	The <scp>MSH2</scp> c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families. Clinical Genetics, 2013, 84, 244-250.	1.0	13

#	Article	IF	Citations
505	The effect of intermittent energy and carbohydrate restrictionv. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. British Journal of Nutrition, 2013, 110, 1534-1547.	1.2	336
506	Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature, 2013, 493, 406-410.	13.7	218
507	Neurofibromatosis Type 1 and Autism Spectrum Disorder. Pediatrics, 2013, 132, e1642-e1648.	1.0	145
508	International variation in physiciansâ€™ attitudes towards prophylactic mastectomy â€“ Comparison between France, Germany, the Netherlands and the United Kingdom. European Journal of Cancer, 2013, 49, 2798-2805.	1.3	24
509	Breast cancer prevention: SERMs come of age. Lancet, The, 2013, 381, 1795-1797.	6.3	6
510	Contralateral breast cancer in high-risk patients: Identification of risk factors to guide recommendations for contralateral prophylactic mastectomy â€“ A 30-year experience. European Journal of Surgical Oncology, 2013, 39, 520.	0.5	1
511	Contralateral risk reducing mastectomy â€“ A national survey of surgeons' practices and perceptions. European Journal of Surgical Oncology, 2013, 39, S64.	0.5	4
512	Mutation type and position varies between mosaic and inherited <scp>NF2</scp> and correlates with disease severity. Clinical Genetics, 2013, 83, 594-595.	1.0	24
513	Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a populationâ€based study. Developmental Medicine and Child Neurology, 2013, 55, 139-145.	1.1	149
514	Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. European Journal of Human Genetics, 2013, 21, 212-216.	1.4	44
515	Is multiple <scp>SNP</scp> testing in <scp>BRCA2</scp> and <scp>BRCA1</scp> female carriers ready for use in clinical practice? Results from a large Genetic Centre in the <scp>UK</scp>. Clinical Genetics, 2013, 84, 37-42.	1.0	12
516	Cancer risk in Lynch Syndrome. Familial Cancer, 2013, 12, 229-240.	0.9	186
517	Familial breast cancer: summary of updated NICE guidance. BMJ, The, 2013, 346, f3829-f3829.	3.0	69
518	The spectrum of urological malignancy in Lynch syndrome. Familial Cancer, 2013, 12, 57-63.	0.9	50
519	Correspondence: Humanitarian Intervention and the Responsibility to Protect. International Security, 2013, 37, 199-214.	1.4	33
520	Reproductive decision-making in young female carriers of a BRCA mutation. Human Reproduction, 2013, 28, 1006-1012.	0.4	62
521	Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis. Journal of Medical Genetics, 2013, 50, 606-613.	1.5	28
522	Mastectomies of healthy, contralateral breasts in patients with breast cancer. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, 486-487.	0.2	1

#	Article	IF	Citations
523	Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotypeâ€“phenotype correlation. European Journal of Human Genetics, 2013, 21, 535-539.	1.4	27
524	Increased Rate of Phenocopies in All Age Groups in BRCA1/BRCA2 Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2269-2276.	1.1	13
525	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	1.5	105
526	Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology, 2013, 81, S33-40.	1.5	107
527	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
528	Can manipulation of splicing offer gene therapy possibilities to those with tumour-prone disorders?. European Journal of Human Genetics, 2013, 21, 701-702.	1.4	1
529	Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. Journal of Clinical Oncology, 2013, 31, 49-57.	0.8	126
530	Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. Neurology, 2013, 81, S25-32.	1.5	36
531	Metachronous colorectal cancer risk in patients with a moderate family history. Colorectal Disease, 2013, 15, 309-316.	0.7	8
532	Successful radiofrequency ablation of an anterior abdominal wall desmoid in familial adenomatous polyposis. Colorectal Disease, 2013, 15, e160-e163.	0.7	9
533	Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative forBRCA1andBRCA2. Journal of Medical Genetics, 2013, 50, 368-372.	1.5	23
534	Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk. International Journal of Cancer, 2013, 133, 156-163.	2.3	20
535	The Fragile X Protein binds m <scp>RNA</scp> s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2013, 5, 1523-1536.	3.3	106
536	Prophylactic mastectomy and breast cancer. British Journal of Hospital Medicine (London, England:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.2	0
537	Same task, same observers, different values: the problem with visual assessment of breast density. , 2013, , .		4
538	Key genetic considerations in the management of suspected hereditary colorectal cancer. Colorectal Cancer, 2013, 2, 31-41.	0.8	0
539	RIC-3 differentially modulates Î±4Î²2 and Î±7 nicotinic receptor assembly, expression, and nicotine-induced receptor upregulation. BMC Neuroscience, 2013, 14, 47.	0.8	29
540	English Consensus Protocol Evaluating Candidacy for Auditory Brainstem and Cochlear Implantation in Neurofibromatosis Type 2. Otology and Neurotology, 2013, 34, 1743-1747.	0.7	26

#	Article	IF	Citations
541	Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Scientific Reports, 2013, 3, 2059.	1.6	26
542	Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors. The Application of Clinical Genetics, 2013, 6, 53.	1.4	16
543	Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	10
544	Evaluation of mammographic surveillance services in women aged 40â€“49 years with a moderate family history of breast cancer: a single-arm cohort study. Health Technology Assessment, 2013, 17, vii-xiv, 1-95.	1.3	11
545	Abstract A35: SMARCE1 mutations cause inherited multiple spinal meningiomas. , 2013, , .		0
546	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
547	Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. European Journal of Human Genetics, 2012, 20, 4-10.	1.4	68
548	Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers?. Journal of Clinical Oncology, 2012, 30, 471-473.	0.8	9
549	Detection and management of women at increased risk of breast cancer. Clinical Practice (London,) Tj ETQq1 1 0.784314 rgBT /Overl	0.1	0
550	Two Out of Three Required. International Journal of Surgical Pathology, 2012, 20, 265-268.	0.4	2
551	Fine-Mapping CASP8 Risk Variants in Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 176-181.	1.1	21
552	BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. British Journal of Cancer, 2012, 106, 1234-1238.	2.9	85
553	Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer, 2012, 106, 775-779.	2.9	22
554	Germline RAD51C mutations confer susceptibility to ovarian cancer. Nature Genetics, 2012, 44, 475-476.	9.4	219
555	Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies. Journal of Clinical Oncology, 2012, 30, 1142-1143.	0.8	5
556	Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1458-1468.	1.1	79
557	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
558	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513

#	Article	IF	Citations
559	Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, The, 2012, 345, e5660-e5660.	3.0	186
560	Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382.	3.8	546
561	Genetic testing and screening of individuals at risk of NF2. Clinical Genetics, 2012, 82, 416-424.	1.0	52
562	Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers. Journal of Clinical Oncology, 2012, 30, 1321-1328.	0.8	31
563	Prevention of breast cancer in the context of a national breast screening programme. Journal of Internal Medicine, 2012, 271, 321-330.	2.7	31
564	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R63.	2.2	22
565	Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. Cancer Prevention Research, 2012, 5, 943-951.	0.7	104
566	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. Cancer Treatment Reviews, 2012, 38, 318-328.	3.4	77
567	Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30â€“49 years?. American Journal of Medical Genetics, Part A, 2012, 158A, 3054-3055.	0.7	10
568	Malignant peripheral nerve sheath tumours in inherited disease. Clinical Sarcoma Research, 2012, 2, 17.	2.3	93
569	Developing National Guidance on Genetic Testing for Breast Cancer Predisposition: The Role of Economic Evidence?. Genetic Testing and Molecular Biomarkers, 2012, 16, 580-591.	0.3	10
570	BRCACarriers, Prophylactic Salpingo-Oophorectomy and Menopause: Clinical Management Considerations and Recommendations. Women's Health, 2012, 8, 543-555.	0.7	75
571	Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncology, The, 2012, 13, 1242-1249.	5.1	95
572	Loss of SUFU Function in Familial Multiple Meningioma. American Journal of Human Genetics, 2012, 91, 520-526.	2.6	137
573	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
574	Life expectancy in hereditary cancer predisposing diseases: an observational study. Journal of Medical Genetics, 2012, 49, 264-269.	1.5	121
575	An improved coverage and spatial resolutionâ€”using dual injection dynamic contrastâ€enhanced (ICEâ€ÐICE) MRI: A novel dynamic contrastâ€enhanced technique for cerebral tumors. Magnetic Resonance in Medicine, 2012, 68, 452-462.	1.9	30
576	Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. International Journal of Cancer, 2012, 131, 417-425.	2.3	23

#	Article	IF	Citations
577	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	2.9	27
578	Geneâ€“gene interactions in breast cancer susceptibility. Human Molecular Genetics, 2012, 21, 958-962.	1.4	41
579	High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?. Breast Cancer Research and Treatment, 2012, 134, 895-897.	1.1	4
580	Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer, 2012, 11, 235-242.	0.9	252
581	Comment on the article â€œGermline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebriâ€• by van den Munckhof et al.. Neurogenetics, 2012, 13, 103-104.	0.7	2
582	Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics, 2012, 13, 141-145.	0.7	114
583	Lack of caveolin-1 (P132L) somatic mutations in breast cancer. Breast Cancer Research and Treatment, 2012, 132, 1185-1186.	1.1	7
584	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2012, 133, 1191-1198.	1.1	36
585	Genetic predisposition to cancer. Medicine, 2012, 40, 29-33.	0.2	2
586	Genotypeâ€“phenotype correlation in colorectal polyposis. Clinical Genetics, 2012, 81, 521-531.	1.0	41
587	Familial Breast Cancer. Clinical Genetics, 2012, 82, 105-114.	1.0	147
588	Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2â€associated gliomas to be spinal ependymomas. Neuropathology, 2012, 32, 611-616.	0.7	28
589	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
590	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
591	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics, Part A, 2012, 158A, 24-41.	0.7	101
592	Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. American Journal of Medical Genetics, Part A, 2012, 158A, 215-219.	0.7	52
593	Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes. Acta Neuropathologica, 2012, 123, 349-367.	3.9	74
594	Volumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) Study. Lecture Notes in Computer Science, 2012, , 228-235.	1.0	6

#	Article	IF	Citations
595	Volumetric and Area-Based Measures of Mammographic Density in Women with and without Cancer. Lecture Notes in Computer Science, 2012, , 589-595.	1.0	3
596	Ethnic Variation in Volumetric Breast Density. Lecture Notes in Computer Science, 2012, , 127-133.	1.0	1
597	Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. European Journal of Human Genetics, 2011, 19, 1187-1191.	1.4	161
598	Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. Journal of Medical Genetics, 2011, 48, 520-522.	1.5	69
599	Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genetics in Medicine, 2011, 13, 576-581.	1.1	89
600	Neurofibromatosis Type 2. Advances in Oto-Rhino-Laryngology, 2011, 70, 91-98.	1.6	40
601	A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome. Journal of Clinical Pathology, 2011, 64, 208-214.	1.0	15
602	Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research, 2011, 71, 5792-5805.	0.4	49
603	Malignant peripheral nerve sheath tumours in NF1: Improved survival in women and in recent years. European Journal of Cancer, 2011, 47, 2723-2728.	1.3	33
604	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	2.2	23
605	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
606	Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, The, 2011, 378, 2081-2087.	6.3	849
607	Hyperplastic Polyps Are Innocuous Lesions in Hereditary Nonpolyposis Colorectal Cancers. International Journal of Surgical Oncology, 2011, 2011, 1-7.	0.3	2
608	Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU International, 2011, 107, 28-39.	1.3	83
609	Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study. British Journal of Cancer, 2011, 104, 578-586.	2.9	22
610	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	2.9	7
611	The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. Cancer Cell, 2011, 19, 273-282.	7.7	104
612	Neurofibromatosis Type 2 (NF2). , 2011, , 47-70.		3

#	Article	IF	Citations
613	Familial breast cancer: is it time to move from a reactive to a proactive role?. Familial Cancer, 2011, 10, 501-503.	0.9	9
614	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Research and Treatment, 2011, 125, 279-287.	1.1	80
615	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	1.8	18
616	Genetic testing for familial/hereditary breast cancerâ€"comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. Journal of Community Genetics, 2011, 2, 53-69.	0.5	59
617	A rapid agonist application system for fast activation of ligand-gated ion channels. Journal of Neuroscience Methods, 2011, 198, 246-254.	1.3	11
618	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. International Journal of Obesity, 2011, 35, 714-727.	1.6	573
619	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
620	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	1.1	16
621	A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. Journal of Medical Genetics, 2011, 48, 256-260.	1.5	90
622	Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor. Clinical Cancer Research, 2011, 17, 31-38.	3.2	191
623	Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. Journal of Medical Genetics, 2011, 48, 261-265.	1.5	101
624	Basal Cell Carcinomas in Gorlin Syndrome: A Review of 202 Patients. Journal of Skin Cancer, 2011, 2011, 1-6.	0.5	99
625	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
626	A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis. Cancer Prevention Research, 2011, 4, 655-665.	0.7	193
627	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
628	Ethnopolitical Conflict: When is it Right to Intervene?. Ethnopolitics, 2011, 10, 115-123.	0.3	3
629	Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics, 2011, 43, 879-882.	9.4	460
630	Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. British Journal of Cancer, 2011, 105, 22-27.	2.9	60

#	Article	IF	Citations
631	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	2.6	91
632	Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?. Journal of Clinical Oncology, 2011, 29, 1501-1501.	0.8	15
633	Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients.. Journal of Clinical Oncology, 2011, 29, 608-608.	0.8	0
634	Effect of WBC BRCA1 promoter methylation on ovarian cancer risk.. Journal of Clinical Oncology, 2011, 29, 5029-5029.	0.8	1
635	Vestibular schwannoma: role of conservative management. Journal of Laryngology and Otology, 2010, 124, 251-257.	0.4	51
636	Birth incidence and prevalence of tumorâ€prone syndromes: Estimates from a UK family genetic register service. American Journal of Medical Genetics, Part A, 2010, 152A, 327-332.	0.7	721
637	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 124, 195-203.	1.1	58
638	Mutation and association analysis of GEN1 in breast cancer susceptibility. Breast Cancer Research and Treatment, 2010, 124, 283-288.	1.1	12
639	Childhood predictive genetic testing for Liâ€“Fraumeni syndrome. Familial Cancer, 2010, 9, 65-69.	0.9	25
640	RASSF1A polymorphism in familial breast cancer. Familial Cancer, 2010, 9, 263-265.	0.9	19
641	Breast cancer susceptibility variants alter risk in familial ovarian cancer. Familial Cancer, 2010, 9, 503-506.	0.9	4
642	Tumor risks and genotypeÃ¢Â€Â“phenotypeÃ¢Â€Â“proteotype analysis in 358 patients with germline mutations inSDHBandSDHD. Human Mutation, 2010, 31, 41-51.	1.1	325
643	Isolated unilateral vestibular schwannomas do not harborHRASmutations. American Journal of Medical Genetics, Part A, 2010, 152A, 1586-1587.	0.7	0
644	Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy. Hereditary Cancer in Clinical Practice, 2010, 8, O5.	0.6	2
645	ORIGINAL ARTICLE: The relationship between patientsâ€™ perception of the effects of neurofibromatosis type 2 and the domains of the Short Formâ€36. Clinical Otolaryngology, 2010, 35, 291-299.	0.6	25
646	Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene, 2010, 29, 6216-6221.	2.6	91
647	Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. British Journal of Cancer, 2010, 102, 1091-1098.	2.9	42
648	Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. British Journal of Cancer, 2010, 103, 918-924.	2.9	118

#	Article	IF	Citations
649	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720.	13.7	737
650	Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome. Histopathology, 2010, 56, 331-344.	1.6	27
651	Genome-wide association study identifies five new breast cancer susceptibility loci. Nature Genetics, 2010, 42, 504-507.	9.4	653
652	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
653	Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 2010, 42, 973-977.	9.4	335
654	Further genotype â€“ phenotype correlations in neurofibromatosis 2. Clinical Genetics, 2010, 77, 163-170.	1.0	94
655	The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine. PLoS ONE, 2010, 5, e13363.	1.1	73
656	SMARCB1 mutations are not a common cause of multiple meningiomas. Journal of Medical Genetics, 2010, 47, 567-568.	1.5	48
657	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
658	Risk of breast cancer in male BRCA2 carriers. Journal of Medical Genetics, 2010, 47, 710-711.	1.5	98
659	Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models. Journal of the National Cancer Institute, 2010, 102, 680-691.	3.0	413
660	Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2. Journal of Laryngology and Otology, 2010, 124, 720-728.	0.4	43
661	Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. JAMA - Journal of the American Medical Association, 2010, 304, 967.	3.8	1,241
662	A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. Journal of Medical Genetics, 2010, 47, 771-774.	1.5	102
663	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	1.1	37
664	The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. Gut, 2010, 59, 1378-1382.	6.1	53
665	Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. Journal of Medical Genetics, 2010, 47, 99-102.	1.5	61
666	BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries. Journal of Medical Genetics, 2010, 47, 561-566.	1.5	7

#	Article	IF	Citations
667	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183.	1.5	85
668	Uptake of breast cancer prevention and screening trials. Journal of Medical Genetics, 2010, 47, 853-855.	1.5	16
669	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102.	2.2	25
670	Breast cancer susceptibility variants alter risks in familial disease. Journal of Medical Genetics, 2010, 47, 126-131.	1.5	35
671	Hormone Replacement Therapy and Breast Cancer. Recent Results in Cancer Research, 2010, 188, 115-124.	1.8	22
672	Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut, 2010, 59, 666-689.	6.1	1,000
673	Development of a Scoring System to Screen for BRCA1/2 Mutations. Methods in Molecular Biology, 2010, 653, 237-247.	0.4	7
674	Update on genetic predisposition to breast cancer. Expert Review of Anticancer Therapy, 2009, 9, 1103-1113.	1.1	11
675	An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). Journal of Medical Genetics, 2009, 46, 792-792.	1.5	22
676	Eligibility for Magnetic Resonance Imaging Screening in the United Kingdom: Effect of Strict Selection Criteria and Anonymous DNA Testing on Breast Cancer Incidence in the MARIBS Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2123-2131.	1.1	14
677	Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2318-2324.	1.1	132
678	Cancers inBRCA1andBRCA2Carriers and in Women at High Risk for Breast Cancer: MR Imaging and Mammographic Features. Radiology, 2009, 252, 358-368.	3.6	67
679	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
680	Outcome from surgery for vestibular schwannomas in children. British Journal of Neurosurgery, 2009, 23, 226-231.	0.4	22
681	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2009, 46, 811-817.	1.5	80
682	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clinical Cancer Research, 2009, 15, 5032-5039.	3.2	74
683	Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 601-610.	1.1	130
684	Sensitization to wheat flour and enzymes and associated respiratory symptoms in British bakers. American Journal of Industrial Medicine, 2009, 52, 133-140.	1.0	25

#	Article	IF	Citations
685	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379.	1.1	12
686	Strategies for endometrial screening in the Lynch syndrome population: a patient acceptability study. Familial Cancer, 2009, 8, 431-439.	0.9	11
687	Pathogenesis of vestibular schwannoma in ring chromosome 22. BMC Medical Genetics, 2009, 10, 97.	2.1	16
688	Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. European Journal of Human Genetics, 2009, 17, 1381-1385.	1.4	28
689	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	9.4	434
690	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2009, 101, 1456-1460.	2.9	19
691	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
692	Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 2009, 75, 141-149.	1.0	280
693	Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives. Clinical Genetics, 2009, 75, 124-132.	1.0	46
694	Increased Colorectal Cancer Incidence in Obligate Carriers of Heterozygous Mutations in MUTYH. Gastroenterology, 2009, 137, 489-494.e1.	0.6	114
695	Neurofibromatosis type 2 (NF2): A clinical and molecular review. Orphanet Journal of Rare Diseases, 2009, 4, 16.	1.2	404
696	Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genetics in Medicine, 2009, 11, 599-610.	1.1	120
697	Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. Breast Cancer Research, 2009, 11, R80.	2.2	77
698	Risk reducing mastectomy: outcomes in 10 European centres. Journal of Medical Genetics, 2009, 46, 254-258.	1.5	80
699	Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. Journal of Medical Genetics, 2009, 46, 593-597.	1.5	116
700	BRCA1/2 mutation analysis in male breast cancer families from North West England. Familial Cancer, 2008, 7, 113-117.	0.9	29
701	Germline and somaticNF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Human Mutation, 2008, 29, 74-82.	1.1	106
702	Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. British Journal of Surgery, 2008, 95, 868-875.	0.1	18

#	Article	IF	Citations
703	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
704	Deciphering the genetics of hereditary non-syndromic colorectal cancer. European Journal of Human Genetics, 2008, 16, 1477-1486.	1.4	31
705	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer, 2008, 98, 1457-1466.	2.9	461
706	A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics, 2008, 40, 623-630.	9.4	514
707	Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clinical Genetics, 2008, 73, 338-345.	1.0	38
708	Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 2008, 74, 233-242.	1.0	85
709	Diagnosed with breast cancer while on a family history screening programme: an exploratory qualitative study. European Journal of Cancer Care, 2008, 17, 245-252.	0.7	12
710	Penetrance estimates for BRCA1 and BRCA2based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer, 2008, 8, 155.	1.1	191
711	A computer-based aid for communication between patients with limited English and their clinicians, using symbols and digitised speech. International Journal of Medical Informatics, 2008, 77, 507-517.	1.6	7
712	Genetic predisposition to cancer. Medicine, 2008, 36, 50-54.	0.2	0
713	Trigeminal schwannomas. British Journal of Neurosurgery, 2008, 22, 729-738.	0.4	56
714	Assessment of in vitro sperm characteristics in relation to fertility in dairy bulls. Animal Reproduction Science, 2008, 103, 201-214.	0.5	131
715	Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Human Molecular Genetics, 2008, 17, 3720-3727.	1.4	61
716	Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause International, 2008, 14, 6-12.	1.6	61
717	Prevalence of Adenomas and Hyperplastic Polyps in Mismatch Repair Mutation Carriers Among CAPP2 Participants: Report by the Colorectal Adenoma/Carcinoma Prevention Programme 2. Journal of Clinical Oncology, 2008, 26, 3434-3439.	0.8	34
718	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337.	0.8	522
719	Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. Journal of Medical Genetics, 2008, 45, 332-339.	1.5	179
720	A Pilot Study of Compositional Analysis of the Breast and Estimation of Breast Mammographic Density Using Three-Dimensional T1-Weighted Magnetic Resonance Imaging. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2268-2274.	1.1	81

#	Article	IF	Citations
721	Inherited predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3. Gut, 2008, 57, 1252-1255.	6.1	51
722	Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1535-1542.	1.1	15
723	Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. New England Journal of Medicine, 2008, 359, 2567-2578.	13.9	273
724	Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients. Clinical Cancer Research, 2008, 14, 5913-5918.	3.2	107
725	What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors?. Journal of Neurosurgery, 2008, 108, 92-96.	0.9	32
726	Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. Journal of Medical Genetics, 2008, 45, 425-431.	1.5	167
727	Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. Journal of Medical Genetics, 2007, 44, 424-428.	1.5	144
728	BRCA2: a cause of Li Fraumeni-like syndrome. Journal of Medical Genetics, 2007, 45, 62-63.	1.5	21
729	Is CHEK2 a cause of the Li Fraumeni syndrome?. Journal of Medical Genetics, 2007, 45, 63-64.	1.5	30
730	Cryopreservation of epididymal alpaca (Vicugna pacos) sperm: a comparison of citrate-, Tris- and lactose-based diluents and pellets and straws. Reproduction, Fertility and Development, 2007, 19, 792.	0.1	37
731	An Absence of Cutaneous Neurofibromas Associated with a 3-bp Inframe Deletion in Exon 17 of the NF1 Gene (c.2970-2972 delAAT): Evidence of a Clinically Significant NF1 Genotype-Phenotype Correlation. American Journal of Human Genetics, 2007, 80, 140-151.	2.6	335
732	Breast cancer risk-assessment models. Breast Cancer Research, 2007, 9, 213.	2.2	142
733	Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes. Science, 2007, 316, 1336-1341.	6.0	2,040
734	Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. Journal of Medical Genetics, 2007, 44, 481-484.	1.5	196
735	Characterization of Troponin Responses in Isoproterenol-Induced Cardiac Injury in the Hanover Wistar Rat. Toxicologic Pathology, 2007, 35, 606-617.	0.9	68
736	Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations. British Journal of Surgery, 2007, 94, 1009-1013.	0.1	53
737	Surveillance for familial breast cancer: Differences in outcome according toBRCA mutation status. International Journal of Cancer, 2007, 121, 1017-1020.	2.3	86
738	PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics, 2007, 39, 165-167.	9.4	858

#	Article	IF	Citations
739	Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. British Journal of Cancer, 2007, 96, 718-724.	2.9	79
740	Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447, 1087-1093.	13.7	2,165
741	Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?. Clinical Genetics, 2007, 71, 354-358.	1.0	49
742	The impact of new screening protocol on individuals at increased risk of colorectal cancer. Colorectal Disease, 2007, 9, 635-640.	0.7	4
743	Bilateral Prophylactic Oophorectomy and Bilateral Prophylactic Mastectomy in a Prospective Cohort of Unaffected BRCA1 and BRCA2 Mutation Carriers. Clinical Breast Cancer, 2007, 7, 875-882.	1.1	77
744	Strategies for Identifying Hereditary Nonpolyposis Colon Cancer. Seminars in Oncology, 2007, 34, 411-417.	0.8	21
745	Familial colorectal cancer referral to regional genetics departmentâ€"a single centre experience. Familial Cancer, 2007, 6, 81-87.	0.9	6
746	Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. Familial Cancer, 2007, 6, 287-294.	0.9	13
747	Delivering cancer genetics services-new ways of working. Familial Cancer, 2007, 6, 163-167.	0.9	17
748	The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30â€"49. European Journal of Health Economics, 2007, 8, 137-144.	1.4	34
749	Estrogen Deprivation for Breast Cancer Prevention. Recent Results in Cancer Research, 2007, 174, 151-167.	1.8	7
750	Parity and breast cancer risk among BRCA1 and BRCA2mutation carriers. Breast Cancer Research, 2006, 8, R72.	2.2	66
751	Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncology, The, 2006, 7, 223-229.	5.1	333
752	Effect of Seminal Plasma Fractions From Entire and Vasectomized Rams on the Motility Characteristics, Membrane Status, and In Vitro Fertility of Ram Spermatozoa. Journal of Andrology, 2006, 28, 109-122.	2.0	22
753	Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. Journal of Medical Genetics, 2006, 44, 81-88.	1.5	778
754	BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. European Journal of Cancer, 2006, 42, 1143-1150.	1.3	139
755	Screening younger women with a family history of breast cancer â€" does early detection improve outcome?. European Journal of Cancer, 2006, 42, 1385-1390.	1.3	42
756	Psychosocial effects of neurofibromatosis type 2 (Part 1): General effects. Audiological Medicine, 2006, 4, 202-210.	0.4	9

#	Article	IF	Citations
757	Predicting Compliance in a Breast Cancer Prevention Trial. Breast Journal, 2006, 12, 446-450.	0.4	20
758	Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes. Clinical Genetics, 2006, 70, 388-395.	1.0	20
759	ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics, 2006, 38, 873-875.	9.4	641
760	Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 2006, 38, 1239-1241.	9.4	636
761	Radiation-induced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance. Child's Nervous System, 2006, 23, 133-136.	0.6	22
762	News on the genetics, epidemiology, medical care and translational research of Schwannomas. Journal of Neurology, 2006, 253, 1533-1541.	1.8	49
763	Extending the Limits of Supertree Methods. Annals of Combinatorics, 2006, 10, 31-51.	0.3	9
764	A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 2006, 45, 646-655.	1.5	111
765	The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Human Mutation, 2006, 27, 716-716.	1.1	46
766	Evaluation ofRAD50 in familial breast cancer predisposition. International Journal of Cancer, 2006, 118, 2911-2916.	2.3	51
767	Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. Clinical Cancer Research, 2006, 12, 7025-7032.	3.2	75
768	Second Primary Tumors in Neurofibromatosis 1 Patients Treated for Optic Glioma: Substantial Risks After Radiotherapy. Journal of Clinical Oncology, 2006, 24, 2570-2575.	0.8	319
769	Optimal Selection of Individuals for BRCA Mutation Testing. Journal of Clinical Oncology, 2006, 24, 3311-3311.	0.8	4
770	Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology, 2006, 66, 730-732.	1.5	143
771	Acute Chemotherapyâ€“Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. Clinical Cancer Research, 2006, 12, 7033-7038.	3.2	36
772	Is It Time to Abandon Microsatellite Instability As a Pre-Screen for Selecting Families for Mutation Testing for Mismatch Repair Genes?. Journal of Clinical Oncology, 2006, 24, 1960-1962.	0.8	11
773	BRCA1 and BRCA2 Cancer Risks. Journal of Clinical Oncology, 2006, 24, 3312-3313.	0.8	26
774	Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Research, 2006, 66, 1866-1872.	0.4	119

#	Article	IF	Citations
775	Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. Journal of Medical Genetics, 2006, 44, 10-15.	1.5	102
776	Evidence for a colorectal cancer susceptibility locus on chromosome 3q21-q24 from a high-density SNP genome-wide linkage scan. Human Molecular Genetics, 2006, 15, 2903-2910.	1.4	52
777	Familial Ovarian Cancer Screening. Journal of Clinical Oncology, 2006, 24, e11-e11.	0.8	0
778	Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaboratorsâ€™ Group. Journal of Clinical Oncology, 2006, 24, 3361-3366.	0.8	188
779	Evidence of Linkage to Chromosome 9q22.33 in Colorectal Cancer Kindreds from the United Kingdom. Cancer Research, 2006, 66, 5003-5006.	0.4	51
780	Pregnancies, Breast-Feeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). Journal of the National Cancer Institute, 2006, 98, 535-544.	3.0	191
781	Evidence for a colorectal cancer susceptibility locus on chromosome 3q21â€“q24 from a high-density SNP genome-wide linkage scan. Human Molecular Genetics, 2006, 15, 3592-3592.	1.4	0
782	Accurate Prediction of BRCA1 and BRCA2 Heterozygous Genotype Using Expression Profiling after Induced DNA Damage. Clinical Cancer Research, 2006, 12, 3896-3901.	3.2	34
783	Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. British Journal of Cancer, 2006, 94, 1021-1028.	2.9	24
784	Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. British Journal of Cancer, 2006, 95, 801-810.	2.9	113
785	A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2?. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 269-271.	0.9	28
786	The development and evaluation of alternative communication strategies to facilitate interactions with Somali refugees in primary care: a preliminary study. Journal of Innovation in Health Informatics, 2006, 14, 183-189.	0.9	6
787	Size and Growth Rate of Sporadic Vestibular Schwannoma: Predictive Value of Information Available at Presentation. Otology and Neurotology, 2005, 26, 86-92.	0.7	60
788	Incidence of Vestibular Schwannoma and Neurofibromatosis 2 in the North West of England over a 10-year Period: Higher Incidence than Previously Thought. Otology and Neurotology, 2005, 26, 93-97.	0.7	328
789	Identification of genetic aberrations on chromosome 22 outside theNF2locus in schwannomatosis and neurofibromatosis type 2. Human Mutation, 2005, 26, 540-549.	1.1	29
790	High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. Human Genetics, 2005, 118, 35-44.	1.8	19
791	Neurofibromatosis 2 (NF2) and Malignant Mesothelioma in a Man with a Constitutional NF2 Missense Mutation. Familial Cancer, 2005, 4, 321-322.	0.9	20
792	Multiple meningiomas: differential involvement of the NF2 gene in children and adults. Journal of Medical Genetics, 2005, 42, 45-48.	1.5	63

#	Article	IF	Citations
793	Diagnostic criteria for schwannomatosis. Neurology, 2005, 64, 1838-1845.	1.5	368
794	Non-random transmission of mutant alleles to female offspring in BRCA carriers. Journal of Medical Genetics, 2005, 42, e6-e6.	1.5	5
795	Screening for Familial Ovarian Cancer: Failure of Current Protocols to Detect Ovarian Cancer at an Early Stage According to the International Federation of Gynecology and Obstetrics System. Journal of Clinical Oncology, 2005, 23, 5588-5596.	0.8	151
796	Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. Clinical Cancer Research, 2005, 11, 5175-5180.	3.2	577
797	Spinal tumors in neurofibromatosis Type 2. Is emerging knowledge of genotype predictive of natural history?. Journal of Neurosurgery: Spine, 2005, 2, 574-579.	0.9	65
798	Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2. Journal of Medical Genetics, 2005, 42, 903-906.	1.5	33
799	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 2005, 42, 602-603.	1.5	121
800	Evidence for an Association between Compound Heterozygosity for Germ Line Mutations in the Hemochromatosis (HFE) Gene and Increased Risk of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1460-1463.	1.1	28
801	The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. Journal of Medical Genetics, 2005, 42, 540-546.	1.5	98
802	Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2005, 42, e39-e39.	1.5	74
803	Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms. Journal of Medical Genetics, 2005, 42, 630-632.	1.5	34
804	Management of the patient and family with neurofibromatosis 2: a consensus conference statement. British Journal of Neurosurgery, 2005, 19, 5-12.	0.4	229
805	Family history of breast cancer. BMJ: British Medical Journal, 2005, 330, 730.1.	2.4	1
806	Sensitive Detection of Deletions of One or More Exons in the Neurofibromatosis Type 2 (NF2) Gene by Multiplexed Gene Dosage Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2005, 7, 97-104.	1.2	13
807	Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. Journal of Clinical Oncology, 2005, 23, 7804-7810.	0.8	396
808	Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. European Journal of Surgical Oncology, 2005, 31, 1112-1118.	0.5	41
809	Mechanisms of Disease: prediction and prevention of breast cancerâ€"cellular and molecular interactions. Nature Clinical Practice Oncology, 2005, 2, 635-646.	4.3	29
810	Neurofibromatosis type 2. , 2004, , 50-59.		1

#	Article	IF	Citations
811	Mutation Scanning of the NF2 Gene: An Improved Service Based on Meta-PCR/Sequencing, Dosage Analysis, and Loss of Heterozygosity Analysis. Genetic Testing and Molecular Biomarkers, 2004, 8, 368-380.	1.7	38
812	Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. Journal of Clinical Oncology, 2004, 22, 1055-1062.	0.8	1,095
813	Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. Journal of Medical Genetics, 2004, 41, 529-534.	1.5	52
814	Psychosocial impact of breast/ovarian (BRCA 1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. British Journal of Cancer, 2004, 91, 1787-1794.	2.9	276
815	Non-Uptake of Predictive Genetic Testing for BRCA1/2 among Relatives of Known Carriers: Attributes, Cancer Worry, and Barriers to Testing in a Multicenter Clinical Cohort. Genetic Testing and Molecular Biomarkers, 2004, 8, 23-29.	1.7	59
816	Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. Journal of Medical Genetics, 2004, 41, 21e-21.	1.5	17
817	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. Journal of Medical Genetics, 2004, 41, 474-480.	1.5	232
818	BRCA1/2 predictive testing: a study of uptake in two centres. European Journal of Human Genetics, 2004, 12, 654-662.	1.4	49
819	Prevention and genetic testing for breast cancer: variations in medical decisions. Social Science and Medicine, 2004, 58, 1085-1096.	1.8	49
820	Molecular stool screening for colorectal cancer. British Journal of Surgery, 2004, 91, 790-800.	0.1	30
821	Eight novelMSH6germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue. Human Mutation, 2004, 23, 285-285.	1.1	28
822	Genotype-Phenotype Correlations for Nervous System Tumors in Neurofibromatosis 2: A Population-Based Study. American Journal of Human Genetics, 2004, 75, 231-239.	2.6	140
823	Patterns of associations of clinical features in neurofibromatosisÂ1 (NF1). Human Genetics, 2003, 112, 289-297.	1.8	49
824	New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemotherapy and Pharmacology, 2003, 52, 39-44.	1.1	29
825	Exploring the â€œtwo-hit hypothesisâ€•in NF2: Tests of two-hit and three-hit models of vestibular schwannoma development. Genetic Epidemiology, 2003, 24, 265-272.	0.6	25
826	Dento-osseous changes as diagnostic markers in familial adenomatous polyposis families. Oral Diseases, 2003, 9, 29-33.	1.5	14
827	Genetic analysis of mitochondrial complex II subunits SDHD , SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clinical Endocrinology, 2003, 59, 728-733.	1.2	97
828	Is clinical growth index a reliable predictor of tumour growth in vestibular schwannomas?. Clinical Otolaryngology, 2003, 28, 85-90.	0.0	27

#	Article	IF	Citations
829	Bayesian evaluation of breast cancer screening using data from two studies. Statistics in Medicine, 2003, 22, 1661-1674.	0.8	8
830	Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet, The, 2003, 361, 1101-1102.	6.3	200
831	Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet, The, 2003, 362, 39-41.	6.3	421
832	Variants in CHEK2 Other than 1100delC Do Not Make a Major Contribution to Breast Cancer Susceptibility. American Journal of Human Genetics, 2003, 72, 1023-1028.	2.6	119
833	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. American Journal of Human Genetics, 2003, 72, 1117-1130.	2.6	3,105
834	Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?. Breast Cancer Research, 2003, 6, E7.	2.2	19
835	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. Journal of Medical Genetics, 2003, 40, 807-814.	1.5	261
836	Abnormalities of the vitreoretinal interface caused by dysregulated Hedgehog signaling during retinal development. Human Molecular Genetics, 2003, 12, 3269-3276.	1.4	41
837	Genotype-phenotype correlations for cataracts in neurofibromatosis 2. Journal of Medical Genetics, 2003, 40, 758-760.	1.5	15
838	Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation. Journal of Medical Genetics, 2003, 40, 802-806.	1.5	70
839	Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families. Journal of Medical Genetics, 2003, 40, 107e-107.	1.5	13
840	Do Women Understand the Odds? Risk Perceptions and Recall of Risk Information in Women with a Family History of Breast Cancer. Public Health Genomics, 2003, 6, 214-223.	0.6	34
841	Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. Journal of Medical Genetics, 2003, 40, 459-463.	1.5	124
842	Neurofibromatosis 2. Current Opinion in Neurology, 2003, 16, 27-33.	1.8	106
843	Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. Cancer Research, 2003, 63, 8596-9.	0.4	48
844	Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. British Journal of Cancer, 2002, 86, 1209-1216.	2.9	173
845	Re: Risk-Reduction Mastectomy: Clinical Issues and Research Needs. Journal of the National Cancer Institute, 2002, 94, 307-307.	3.0	4
846	Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2Mutations. New England Journal of Medicine, 2002, 346, 1616-1622.	13.9	1,565

#	Article	IF	Citations
847	Neurofibromatosis type 1 and sporadic optic gliomas. Archives of Disease in Childhood, 2002, 87, 65-70.	1.0	135
848	Risk assessment and management of high risk familial breast cancer. Journal of Medical Genetics, 2002, 39, 865-871.	1.5	53
849	Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 827-831.	3.3	73
850	Germline mutation of ARF in a melanoma kindred. Human Molecular Genetics, 2002, 11, 1273-1279.	1.4	120
851	Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology, 2002, 59, 1759-1765.	1.5	215
852	Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. Journal of Medical Genetics, 2002, 39, 315-322.	1.5	65
853	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779.	3.0	318
854	Predictors of the Risk of Mortality in Neurofibromatosis 2. American Journal of Human Genetics, 2002, 71, 715-723.	2.6	211
855	Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics,BRCAmutations and oophorectomy. International Journal of Cancer, 2002, 101, 555-559.	2.3	99
856	Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). Genetic Epidemiology, 2002, 23, 245-259.	0.6	23
857	Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene, 2002, 21, 1928-1933.	2.6	85
858	Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics, 2002, 31, 55-59.	9.4	1,001
859	A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients. British Journal of Cancer, 2002, 86, 718-722.	2.9	13
860	There may never be a final cure for breast cancer. European Journal of Surgical Oncology, 2001, 27, 338-339.	0.5	2
861	Germline SDHD mutation in familial phaeochromocytoma. Lancet, The, 2001, 357, 1181-1182.	6.3	236
862	Uptake of screening and prevention in women at very high risk of breast cancer. Lancet, The, 2001, 358, 889-890.	6.3	56
863	Screening of patients at high risk of colorectal cancer. Colorectal Disease, 2001, 3, 308-311.	0.7	4
864	Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another. Cancer, 2001, 92, 959-968.	2.0	98

#	Article	IF	Citations
865	High detection rate for BRCA2 mutations in male breast cancer families from North West England. Familial Cancer, 2001, 1, 131-133.	0.9	12
866	Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Familial Cancer, 2001, 1, 65-72.	0.9	45
867	Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene, 2001, 20, 4621-4628.	2.6	410
868	Molecular genetics and endometrial cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2001, 15, 355-363.	1.4	6
869	High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Human Molecular Genetics, 2001, 10, 271-282.	1.4	147
870	Germline mutation analysis of the transforming growth factor beta receptor type II (TGFBR2) and E-cadherin (CDH1) genes in early onset and familial colorectal cancer. Journal of Medical Genetics, 2001, 38, 7e-7.	1.5	3
871	Re: Characterization of Hereditary Nonpolyposis Colorectal Cancer Families From a Population-Based Series of Cases. Journal of the National Cancer Institute, 2001, 93, 716-717.	3.0	6
872	Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. Journal of Medical Genetics, 2001, 38, 139-139.	1.5	100
873	Advances in Neurofibromatosis 2 (NF2): A Workshop Report. Journal of Neurogenetics, 2000, 14, 63-106.	0.6	33
874	Lack of sex-ratio distortion in neurofibromatosis 2. American Journal of Medical Genetics Part A, 2000, 95, 292-292.	2.4	4
875	Associations of clinical features in neurofibromatosis 1 (NF1). Genetic Epidemiology, 2000, 19, 429-439.	0.6	79
876	Clinical follow-up after bilateral risk reducing (?prophylactic?) mastectomy: mental health and body image outcomes. Psycho-Oncology, 2000, 9, 462-472.	1.0	121
877	Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. Magnetic Resonance Imaging, 2000, 18, 765-776.	1.0	104
878	Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genetics, 2000, 25, 160-165.	9.4	640
879	No useful role for fine needle aspiration as a marker for familial breast cancer. Breast, 2000, 9, 218-219.	0.9	0
880	Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast, 2000, 9, 72-77.	0.9	24
881	Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast, 2000, 9, 78-82.	0.9	22
882	Management of the contralateral breast in patients with hereditary breast cancer. Breast, 2000, 9, 301-305.	0.9	2

#	Article	IF	Citations
883	Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. British Journal of Cancer, 2000, 82, 998-998.	2.9	120
884	Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13. Human Genetics, 2000, 106, 58-65.	1.8	51
885	A survey of the current clinical facilities for the management of familial cancer in Europe. Journal of Medical Genetics, 2000, 37, 605-607.	1.5	15
886	Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. Journal of Medical Genetics, 2000, 37, 203-209.	1.5	106
887	Stereotactic radiosurgery XI. Acoustic neuroma therapy and radiation oncogenesis. British Journal of Neurosurgery, 2000, 14, 93-95.	0.4	15
888	Can hair be used to screen for breast cancer?. Journal of Medical Genetics, 2000, 37, 297-298.	1.5	14
889	Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut, 2000, 46, 656-660.	6.1	117
890	Clinical and molecular correlates of somatic mosaicism in neurofibromatosis 2. Journal of Medical Genetics, 2000, 37, 542-543.	1.5	8
891	Recurrent germline mutation in MSH2 arises frequently de novo. Journal of Medical Genetics, 2000, 37, 646-652.	1.5	72
892	2157delG: a frequent mutation in BRCA2 missed by PTT. Journal of Medical Genetics, 2000, 37, 42e-42.	1.5	9
893	Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2). Journal of Medical Genetics, 2000, 37, 944-947.	1.5	30
894	Variation in prophylactic surgery decisions. Lancet, The, 2000, 356, 1687.	6.3	12
895	A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. European Journal of Surgical Oncology, 2000, 26, 711-713.	0.5	35
896	Hereditary cancer. Lancet Oncology, The, 2000, 1, 12.	5.1	0
897	Neurofibromatosis type 2. Journal of Medical Genetics, 2000, 37, 897-904.	1.5	165
898	Genetic and cytogenetic studies in inherited cancer: Li-Fraumeni syndrome. , 2000, , 245-255.		0
899	Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Disease Markers, 1999, 15, 207-211.	0.6	55
900	Cancer Genetics Services in Europe. Disease Markers, 1999, 15, 3-13.	0.6	14

#	Article	IF	Citations
901	Insurance Implications for Individuals with a High Risk of Breast and Ovarian Cancer in Europe. Disease Markers, 1999, 15, 159-165.	0.6	13
902	Genetic Testing for Breast Cancer Predisposition in 1999: Which Molecular Strategy and which Family Criteria?. Disease Markers, 1999, 15, 67-68.	0.6	4
903	Ethical, Social and Economic Issues in Familial Breast Cancer: A Compilation of Views from the E.C. Biomed II Demonstration Project. Disease Markers, 1999, 15, 125-131.	0.6	23
904	Utilisation of Prophylactic Mastectomy in 10 European Centres. Disease Markers, 1999, 15, 148-151.	0.6	29
905	Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer. Disease Markers, 1999, 15, 179-186.	0.6	35
906	Management of Hereditary Breast Cancer. Disease Markers, 1999, 15, 187-189.	0.6	8
907	Risk Estimation as a Decision-Making Tool for Genetic Analysis of the Breast Cancer Susceptibility Genes. Disease Markers, 1999, 15, 53-65.	0.6	8
908	Neurofibromatosis Type 2: Genetic and Clinical Features. Ear, Nose and Throat Journal, 1999, 78, 97-100.	0.4	28
909	Germline E-cadherin Gene (CDH1) Mutations Predispose to Familial Gastric Cancer and Colorectal Cancer. Human Molecular Genetics, 1999, 8, 607-610.	1.4	312
910	Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 764-767.	0.9	54
911	Paediatric presentation of type 2 neurofibromatosis. Archives of Disease in Childhood, 1999, 81, 496-499.	1.0	180
912	Differences AmongHelicobacter pyloriStrains Isolated from Three Different Populations and Demonstrated by Restriction Enzyme Analysis of an Internal Fragment of the Conserved GenehpaA. Helicobacter, 1999, 4, 82-88.	1.6	8
913	The pathology of familial breast cancer: Clinical and geneticcounselling implications of breast cancer pathology. Breast Cancer Research, 1999, 1, 48-51.	2.2	10
914	The Fanconi Anemia Group E Gene, FANCE, Maps to Chromosome 6p. American Journal of Human Genetics, 1999, 64, 1400-1405.	2.6	48
915	Are There Low-Penetrance TP53 Alleles? Evidence from Childhood Adrenocortical Tumors. American Journal of Human Genetics, 1999, 65, 995-1006.	2.6	240
916	The Genetic Epidemiology of Early-Onset Epithelial Ovarian Cancer: A Population-Based Study. American Journal of Human Genetics, 1999, 65, 1725-1732.	2.6	69
917	Heritability of Cellular Radiosensitivity: A Marker of Low-Penetrance Predisposition Genes in Breast Cancer?. American Journal of Human Genetics, 1999, 65, 784-794.	2.6	186
918	A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. Journal of Medical Genetics, 1999, 36, 97-102.	1.5	66

#	Article	IF	Citations
919	A clinical study of type 1 neurofibromatosis in north west England. Journal of Medical Genetics, 1999, 36, 197-203.	1.5	137
920	The accuracy of diagnoses as reported in families with cancer: a retrospective study. Journal of Medical Genetics, 1999, 36, 309-12.	1.5	80
921	Mononucleotide microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. Journal of Medical Genetics, 1999, 36, 678-82.	1.5	59
922	Genetic and functional studies of a germline TP53 splicing mutation in a Liâ€“Fraumeni-like family. Oncogene, 1998, 16, 3291-3298.	2.6	49
923	Cancer phenotype correlates with constitutional TP53 genotype in families with the Liâ€“Fraumeni syndrome. Oncogene, 1998, 17, 1061-1068.	2.6	180
924	A novel TP53 splicing mutation in a Li-Fraumeni syndrome family: a patient with Wilms' tumour is not a mutation carrier. British Journal of Cancer, 1998, 78, 1081-1083.	2.9	16
925	Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. , 1998, 7, 402-412.		104
926	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). Lancet, The, 1998, 352, 1222.	6.3	11
927	Molecular genetic tests in surgical management of familial adenomatous polyposis. Lancet, The, 1998, 351, 1131-1132.	6.3	5
928	Screening by mammography, women with a family history of breast cancer. European Journal of Cancer, 1998, 34, 937-940.	1.3	82
929	Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Journal of Cancer, 1998, 34, 1922-1926.	1.3	105
930	False family history of breast cancer in the family cancer clinic. European Journal of Surgical Oncology, 1998, 24, 275-279.	0.5	23
931	Somatic Mosaicism: A Common Cause of Classic Disease in Tumor-Prone Syndromes? Lessons from Type 2 Neurofibromatosis. American Journal of Human Genetics, 1998, 63, 727-736.	2.6	57
932	Oral Contraceptives and the Risk of Hereditary Ovarian Cancer. New England Journal of Medicine, 1998, 339, 424-428.	13.9	591
933	An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.. Journal of Medical Genetics, 1998, 35, 10-12.	1.5	11
934	Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.. Journal of Medical Genetics, 1998, 35, 973-977.	1.5	23
935	Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.. Journal of Medical Genetics, 1998, 35, 450-455.	1.5	185
936	Men in breast cancer families: a preliminary qualitative study of awareness and experience.. Journal of Medical Genetics, 1998, 35, 739-744.	1.5	58

#	Article	IF	Citations
937	A system for enabling blind people to identify landmarks: the sound buoy. IEEE Transactions on Rehabilitation Engineering: A Publication of the IEEE Engineering in Medicine and Biology Society, 1997, 5, 276-278.	1.4	25
938	Physical localisation of the breakpoints of a constitutional translocation t(5;6)(q21;q21) in a child with bilateral Wilms' tumour.. Journal of Medical Genetics, 1997, 34, 343-345.	1.5	20
939	Uptake of genetic testing for cancer predisposition.. Journal of Medical Genetics, 1997, 34, 746-748.	1.5	68
940	Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 361-366.	0.9	79
941	Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.. Journal of Medical Genetics, 1997, 34, 934-936.	1.5	28
942	The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. British Journal of Cancer, 1997, 76, 141-145.	2.9	118
943	Molecular genetic tests in surgical management of familial adenomatous polyposis. Lancet, The, 1997, 350, 1777.	6.3	16
944	A detailed study of loss of heterozygosity on chromosome 17 in tumours from Liâ€‰â€“â€‰Fraumeni patients carrying a mutation to the TP53 gene. Oncogene, 1997, 14, 865-871.	2.6	98
945	Li-Fraumeni syndrome â€“ a molecular and clinical review. British Journal of Cancer, 1997, 76, 1-14.	2.9	324
946	Risk of subsequent primary cancers in patients with carcinoma of the Ampulla of Vater. British Journal of Cancer, 1997, 76, 1232-1233.	2.9	3
947	APC mutations in familial adenomatous polyposis families in the Northwest of England. Human Mutation, 1997, 10, 376-380.	1.1	40
948	Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Research, 1997, 57, 3245-52.	0.4	198
949	Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. Human Molecular Genetics, 1996, 5, 1921-1924.	1.4	134
950	MSH2 sequence variations and inherited colorectal cancer susceptibility. European Journal of Cancer, 1996, 32, 178.	1.3	11
951	Cancer genetics clinics. European Journal of Cancer, 1996, 32, 391-392.	1.3	22
952	Fictitious breast cancer family history. Lancet, The, 1996, 348, 1034.	6.3	20
953	A clinical, genetic and audiological study of patients and families with unilateral vestibular schwannomas. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas. Journal of Laryngology and Otology, 1996, 110, 634-640.	0.4	16
954	A novel deletion within exon 6 of TP53 in a family with Li-Fraumeni-like syndrome, and LOH in a benign lesion from a mutation carrier. Cancer Genetics and Cytogenetics, 1996, 90, 14-16.	1.0	11

#	Article	IF	Citations
955	Genetic markers for breast cancer. Breast, 1996, 5, 374-376.	0.9	1
956	Florid oral manifestations in an atypical familial adenomatous polyposis family with late presentation of colorectal polyps. Journal of Oral Pathology and Medicine, 1996, 25, 459-462.	1.4	2
957	Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome.. Journal of Medical Genetics, 1996, 33, 726-730.	1.5	49
958	A genetic register for von Hippel-Lindau disease.. Journal of Medical Genetics, 1996, 33, 120-127.	1.5	215
959	Microsatellite instability in early onset and familial colorectal cancer.. Journal of Medical Genetics, 1996, 33, 981-985.	1.5	36
960	Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clinical Genetics, 1996, 49, 59-64.	1.0	77
961	The ethics of testing for cancer-predisposition genes. , 1996, , 383-393.		2
962	A clinical, genetic and audiological study of patients and families with unilateral vestibular schwannomas. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas. Journal of Laryngology and Otology, 1996, 110, 634-40.	0.4	7
963	Variation of expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannomas, but confirmation of a preponderance of meningiomas in females. Journal of Laryngology and Otology, 1995, 109, 830-835.	0.4	23
964	Eleven novel mutations in the NF2 tumour suppressor gene. Human Genetics, 1995, 95, 572-4.	1.8	22
965	Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotypeâ€“phenotype correlation. Nature Genetics, 1995, 11, 428-433.	9.4	484
966	â€˜Should I Take HRT, Doctor?â€™ Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease. The Journal of the British Menopause Society, 1995, 1, 9-17.	1.3	3
967	Suggested Screening Guidelines for Familial Colorectal Cancer. Journal of Medical Screening, 1995, 2, 45-51.	1.1	23
968	An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53.. Journal of Medical Genetics, 1995, 32, 942-945.	1.5	70
969	WAGR syndrome and multiple exostoses in a patient with del(11)(p11.2p14.2). Journal of Medical Genetics, 1995, 32, 823-824.	1.5	28
970	Genetic testing for cancer predisposition: need and demand.. Journal of Medical Genetics, 1995, 32, 161-161.	1.5	3
971	Diagnostic issues in a family with late onset type 2 neurofibromatosis.. Journal of Medical Genetics, 1995, 32, 470-474.	1.5	27
972	Genetic linkage analysis in hereditary non-polyposis colon cancer syndrome.. Journal of Medical Genetics, 1995, 32, 352-357.	1.5	26

#	Article	IF	Citations
973	Genetic evidence for host specificity in the adhesin-encoding genes hxaA of Helicobacter acinonyx, hnaA of H. nemestrinae and hpaA of H. pylori. Gene, 1995, 163, 97-102.	1.0	11
974	Molecular genetic analysis of exons 1 to 6 of the APC gene in nonâ€polyposis familial colorectal cancer. Clinical Genetics, 1995, 48, 299-303.	1.0	8
975	Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Human Molecular Genetics, 1994, 3, 813-816.	1.4	106
976	Detailed mapping of germline deletions of the von Hippelâ€"Lindau disease tumour suppressor gene. Human Molecular Genetics, 1994, 3, 595-598.	1.4	81
977	The impact of genetic counselling on risk perception in women with a family history of breast cancer. British Journal of Cancer, 1994, 70, 934-938.	2.9	168
978	Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Molecular and Cellular Probes, 1994, 8, 519-525.	0.9	69
979	Nonâ€expression of von Hippelâ€Lindau phenotype in an obligate gene carrier. Clinical Genetics, 1994, 45, 104-106.	1.0	8
980	Fortnightly Review: Familial breast cancer. BMJ: British Medical Journal, 1994, 308, 183-187.	2.4	71
981	A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. American Journal of Human Genetics, 1994, 55, 69-73.	2.6	51
982	Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry. Cancer, 1993, 72, 819-827.	2.0	30
983	Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. Medical and Pediatric Oncology, 1993, 21, 433-434.	1.0	39
984	Non-penetrance and late appearance of polyps in families with familial adenomatous polyposis.. Gut, 1993, 34, 1389-1393.	6.1	29
985	A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Human Molecular Genetics, 1993, 2, 701-704.	1.4	57
986	Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.. Journal of Medical Genetics, 1993, 30, 460-464.	1.5	485
987	Perception of risk in women with a family history of breast cancer. British Journal of Cancer, 1993, 67, 612-614.	2.9	162
988	A clinical, genetic and audiological study of patients and families with bilateral acoustic neurofibromatosis. Journal of Laryngology and Otology, 1993, 107, 6-11.	0.4	10
989	Type 2 neurofibromatosis: the need for supraregional care?. Journal of Laryngology and Otology, 1993, 107, 401-406.	0.4	53
990	A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling.. Journal of Medical Genetics, 1992, 29, 847-852.	1.5	146

#	Article	IF	Citations
991	A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.. Journal of Medical Genetics, 1992, 29, 841-846.	1.5	421
992	Ovarian cancer family and prophylactic choices.. Journal of Medical Genetics, 1992, 29, 416-418.	1.5	18
993	Location of gene for Gorlin syndrome. Lancet, The, 1992, 339, 581-582.	6.3	382
994	Allele losses in the region 17q12â€“21 in familial breast and ovarian cancer involve the wildâ€“type chromosome. Nature Genetics, 1992, 2, 128-131.	9.4	387
995	A clinical study of type 2 neurofibromatosis. The Quarterly Journal of Medicine, 1992, 84, 603-18.	1.0	348
996	Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. British Journal of Neurosurgery, 1991, 5, 643-646.	0.4	50
997	Heredity and dysmorphic syndromes in congenital limb deficiencies. Prosthetics and Orthotics International, 1991, 15, 70-77.	0.5	3
998	The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. British Journal of Cancer, 1991, 64, 959-961.	2.9	284
999	Fatal congenital cytomegalovirus infection acquired by an intra-uterine transfusion. European Journal of Pediatrics, 1991, 150, 780-781.	1.3	21
1000	Space Infections of the Head and Neck - The "New" Clinical Picture. Journal of the Royal Army Medical Corps, 1991, 137, 35-37.	0.8	0
1001	Family implications of neonatal Gorlin's syndrome.. Archives of Disease in Childhood, 1991, 66, 1162-1163.	1.0	24
1002	Dominantly inherited microcephaly, hypotelorism and normal intelligence. Clinical Genetics, 1991, 39, 178-180.	1.0	14
1003	Cutaneous lymphangioma and amegakaryocytic thrombocytopenia in Noonan syndrome. Clinical Genetics, 1991, 39, 228-232.	1.0	22
1004	Ankyloblepharon filiforme adnatum in trisomy 18 Edwards syndrome.. Journal of Medical Genetics, 1990, 27, 720-721.	1.5	12